<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<html>
 <body>
  <pubmedarticleset>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="In-Process">
     <pmid version="1">
      32297723
     </pmid>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       17
      </day>
     </daterevised>
     <article pubmodel="Electronic">
      <journal>
       <issn issntype="Print">
        1122-0643
       </issn>
       <journalissue citedmedium="Internet">
        <volume>
         90
        </volume>
        <issue>
         1
        </issue>
        <pubdate>
         <year>
          2020
         </year>
         <month>
          Apr
         </month>
         <day>
          16
         </day>
        </pubdate>
       </journalissue>
       <title>
        Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace
       </title>
       <isoabbreviation>
        Monaldi Arch Chest Dis
       </isoabbreviation>
      </journal>
      <articletitle>
       COVID-2019: update on epidemiology, disease spread and management.
      </articletitle>
      <elocationid eidtype="doi" validyn="Y">
       10.4081/monaldi.2020.1292
      </elocationid>
      <abstract>
       <abstracttext>
        With each passing day, more cases of Coronavirus disease (COVID-2019) are being detected and unfortunately the fear of novel corona virus 2019 (2019-nCoV) becoming a pandemic disease has come true. Constant efforts at individual, national, and international level are being made in order to understand the genomics, hosts, modes of transmission and epidemiological link of nCoV-2019. As of now, whole genome sequence of the newly discovered coronavirus has already been decoded. Genomic characterization nCoV-2019 have shown close homology with bat-derived severe acute respiratory syndrome (SARS)-like coronaviruses, bat-SL-CoVZC45 and bat-SL-CoVZXC21. Structural analysis of the receptor binding site has confirmed that 2019-nCoV binds with the same ACE 2 receptor protein as human SARS virus. Compared to the previous coronavirus outbreaks, the overall mortality rate is relatively low for COVID-2019 (2-3%). Suspected cases must be quarantined till their test comes positive or they clear infection. At present, treatment of COVID-2019 is mostly based on the knowledge gained from the SARS and MERS outbreaks. Remdesivir, originally develop as a treatment for Ebola virus disease and Marburg virus infections, is being studied for it effectiveness against 2019-nCoV infection. Many other antiviral agents and vaccines are being tested but most of them are in phase I or II and hence unlikely to be of any benefit immediately with regards to current outbreak. Hence, the standard infection control techniques and preventive steps for healthy individuals and supportive care for the confirmed cases is the best available strategy to deal with current viral outbreak. .
       </abstracttext>
      </abstract>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Sahu
        </lastname>
        <forename>
         Kamal Kant
        </forename>
        <initials>
         KK
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Internal medicine, Saint Vincent Hospital, Worcester, Massachusetts, United States of America, 01608. Kamalkant.Sahu@stvincenthospital.com.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Mishra
        </lastname>
        <forename>
         Ajay Kumar
        </forename>
        <initials>
         AK
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Internal medicine, Saint Vincent Hospital, Worcester, Massachusetts, United States of America, 01608. Ajaybalasore@gmail.com.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Lal
        </lastname>
        <forename>
         Amos
        </forename>
        <initials>
         A
        </initials>
        <affiliationinfo>
         <affiliation>
          Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester. manavamos@gmail.com.
         </affiliation>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <publicationtypelist>
       <publicationtype ui="D016428">
        Journal Article
       </publicationtype>
      </publicationtypelist>
      <articledate datetype="Electronic">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        16
       </day>
      </articledate>
     </article>
     <medlinejournalinfo>
      <country>
       Italy
      </country>
      <medlineta>
       Monaldi Arch Chest Dis
      </medlineta>
      <nlmuniqueid>
       9307314
      </nlmuniqueid>
      <issnlinking>
       1122-0643
      </issnlinking>
     </medlinejournalinfo>
     <citationsubset>
      IM
     </citationsubset>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="received">
       <year>
        2020
       </year>
       <month>
        03
       </month>
       <day>
        31
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="accepted">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        10
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        17
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        17
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        17
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      epublish
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32297723
      </articleid>
      <articleid idtype="doi">
       10.4081/monaldi.2020.1292
      </articleid>
     </articleidlist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="Publisher">
     <pmid version="1">
      32297571
     </pmid>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       16
      </day>
     </daterevised>
     <article pubmodel="Print-Electronic">
      <journal>
       <issn issntype="Electronic">
        1875-533X
       </issn>
       <journalissue citedmedium="Internet">
        <pubdate>
         <year>
          2020
         </year>
         <month>
          Apr
         </month>
         <day>
          16
         </day>
        </pubdate>
       </journalissue>
       <title>
        Current medicinal chemistry
       </title>
       <isoabbreviation>
        Curr. Med. Chem.
       </isoabbreviation>
      </journal>
      <articletitle>
       SARS CoV-2: Recent Reports on Antiviral Therapies Based on Lopinavir/Ritonavir, Darunavir/Umifenovir, Hydroxychloroquine, Remdesivir, Favipiravir and Other Drugs for the Treatment of the New Coronavirus.
      </articletitle>
      <elocationid eidtype="doi" validyn="Y">
       10.2174/0929867327666200416131117
      </elocationid>
      <abstract>
       <abstracttext>
        Here we report on the most recent updates on experimental drugs successfully employed in the treatment of the disease caused by SARS CoV-2 coronavirus, also referred to as COVID-19 (COronaVIrus Disease 19). In particular, several cases of recovered patients have been reported after being treated with lopinavir/ritonavir (which is widely used to treat human immunodeficiency virus (HIV) infection) in combination with the anti-flu drug oseltamivir. In addition, remdesivir, which has been previously administered to Ebola virus patients, has also proven effective in the U.S. against coronavirus, while antimalarial chloroquine and hydroxychloroquine, favipiravir and co-administered darunavir and umifenovir (in patient therapies) were also recently recorded as having anti-SARS CoV-2 effects. Since the recoveries/deaths ratio in the last weeks significantly increased, especially in China, it is clear that the experimental antiviral therapy, together with the availability of intensive care unit beds in hospitals and rigorous government control measures, all play an important role in dealing with this virus. This also stresses the urgent need for the scientific community to devote its efforts to find other more specific antiviral strategies.
       </abstracttext>
       <copyrightinformation>
        Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.
       </copyrightinformation>
      </abstract>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Costanzo
        </lastname>
        <forename>
         Michele
        </forename>
        <initials>
         M
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Molecular Medicine and Medical Biotechnology, School of Medicine, University of Naples 'Federico II', Via S. Pansini 5, I-80131 Naples. Italy.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         De Giglio
        </lastname>
        <forename>
         Maria Anna Rachele
        </forename>
        <initials>
         MAR
        </initials>
        <affiliationinfo>
         <affiliation>
          School of Medicine and Surgery, University of Naples 'Federico II', Via S. Pansini 5, I-80131 Naples. Italy.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Roviello
        </lastname>
        <forename>
         Giovanni Nicola
        </forename>
        <initials>
         GN
        </initials>
        <affiliationinfo>
         <affiliation>
          Istituto di Biostrutture e Bioimmagini IBB - CNR; Via Mezzocannone 16, I80134 Naples. Italy.
         </affiliation>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <publicationtypelist>
       <publicationtype ui="D016428">
        Journal Article
       </publicationtype>
      </publicationtypelist>
      <articledate datetype="Electronic">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        16
       </day>
      </articledate>
     </article>
     <medlinejournalinfo>
      <country>
       United Arab Emirates
      </country>
      <medlineta>
       Curr Med Chem
      </medlineta>
      <nlmuniqueid>
       9440157
      </nlmuniqueid>
      <issnlinking>
       0929-8673
      </issnlinking>
     </medlinejournalinfo>
     <citationsubset>
      IM
     </citationsubset>
     <keywordlist owner="NOTNLM">
      <keyword majortopicyn="N">
       COVID-19
      </keyword>
      <keyword majortopicyn="N">
       Coronavirus
      </keyword>
      <keyword majortopicyn="N">
       SARS CoV-2
      </keyword>
      <keyword majortopicyn="N">
       antiviral drugs
      </keyword>
      <keyword majortopicyn="N">
       favirapivir
      </keyword>
      <keyword majortopicyn="N">
       hydroxychloroquine
      </keyword>
      <keyword majortopicyn="N">
       lopinavir
      </keyword>
      <keyword majortopicyn="N">
       remdesivir
      </keyword>
      <keyword majortopicyn="N">
       ritonavir.
      </keyword>
     </keywordlist>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="received">
       <year>
        2020
       </year>
       <month>
        02
       </month>
       <day>
        13
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="revised">
       <year>
        2020
       </year>
       <month>
        03
       </month>
       <day>
        27
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="accepted">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        04
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        17
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        17
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        17
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      aheadofprint
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32297571
      </articleid>
      <articleid idtype="pii">
       CMC-EPUB-105865
      </articleid>
      <articleid idtype="doi">
       10.2174/0929867327666200416131117
      </articleid>
     </articleidlist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="Publisher">
     <pmid version="1">
      32294562
     </pmid>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       18
      </day>
     </daterevised>
     <article pubmodel="Print-Electronic">
      <journal>
       <issn issntype="Electronic">
        1873-0442
       </issn>
       <journalissue citedmedium="Internet">
        <pubdate>
         <year>
          2020
         </year>
         <month>
          Apr
         </month>
         <day>
          12
         </day>
        </pubdate>
       </journalissue>
       <title>
        Travel medicine and infectious disease
       </title>
       <isoabbreviation>
        Travel Med Infect Dis
       </isoabbreviation>
      </journal>
      <articletitle>
       A search for medications to treat COVID-19 via in silico molecular docking models of the SARS-CoV-2 spike glycoprotein and 3CL protease.
      </articletitle>
      <pagination>
       <medlinepgn>
        101646
       </medlinepgn>
      </pagination>
      <elocationid eidtype="pii" validyn="Y">
       S1477-8939(20)30115-0
      </elocationid>
      <elocationid eidtype="doi" validyn="Y">
       10.1016/j.tmaid.2020.101646
      </elocationid>
      <abstract>
       <abstracttext label="BACKGROUND" nlmcategory="BACKGROUND">
        The COVID-19 has now been declared a global emergency by the World Health Organization. There is an emergent need to search for possible medications.
       </abstracttext>
       <abstracttext label="METHOD" nlmcategory="METHODS">
        Utilization of the available sequence information, homology modeling, and in slico docking a number of available medications might prove to be effective in inhibiting the COVID-19 two main drug targets the spike glycoprotein and the 3CL protease.
       </abstracttext>
       <abstracttext label="RESULTS" nlmcategory="RESULTS">
        Several compounds were determined from the in silico docking models that might prove to be effective inhibitor for the COVID-19. Several antiviral medications: Zanamivir, Indinavir, Saquinavir, and Remdesivir show potential as and 3CL
        <sup>
         PRO
        </sup>
        main proteinase inhibitors and as a treatment of COVID-19.
       </abstracttext>
       <abstracttext label="CONCLUSION" nlmcategory="CONCLUSIONS">
        Zanamivir, Indinavir, Saquinavir, and Remdesivir are among the exciting hits on the 3CL
        <sup>
         PRO
        </sup>
        main proteinase. It is also exciting to uncover that Flavin Adenine Dinucleotide (FAD) Adeflavin, B2 Deficiency medicine, and Coenzyme A, a coenzyme, may also be potentially used for the treatment of SARS-CoV-2 infections. The use of these off-label medications may be beneficial in the treatment of the COVID-19.
       </abstracttext>
       <copyrightinformation>
        Copyright © 2020. Published by Elsevier Ltd.
       </copyrightinformation>
      </abstract>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Hall
        </lastname>
        <forename>
         Donald C
        </forename>
        <initials>
         DC
        </initials>
        <suffix>
         Jr
        </suffix>
        <affiliationinfo>
         <affiliation>
          Department of Chemistry, Drexel University, Philadelphia, PA, 19104, USA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Ji
        </lastname>
        <forename>
         Hai-Feng
        </forename>
        <initials>
         HF
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Chemistry, Drexel University, Philadelphia, PA, 19104, USA. Electronic address: hj56@drexel.edu.
         </affiliation>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <publicationtypelist>
       <publicationtype ui="D016428">
        Journal Article
       </publicationtype>
      </publicationtypelist>
      <articledate datetype="Electronic">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        12
       </day>
      </articledate>
     </article>
     <medlinejournalinfo>
      <country>
       Netherlands
      </country>
      <medlineta>
       Travel Med Infect Dis
      </medlineta>
      <nlmuniqueid>
       101230758
      </nlmuniqueid>
      <issnlinking>
       1477-8939
      </issnlinking>
     </medlinejournalinfo>
     <citationsubset>
      IM
     </citationsubset>
     <keywordlist owner="NOTNLM">
      <keyword majortopicyn="N">
       Approved drugs
      </keyword>
      <keyword majortopicyn="N">
       Coronavirus
      </keyword>
      <keyword majortopicyn="N">
       Medications
      </keyword>
      <keyword majortopicyn="N">
       Molecular docking
      </keyword>
      <keyword majortopicyn="N">
       SARS-CoV-2
      </keyword>
     </keywordlist>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="received">
       <year>
        2020
       </year>
       <month>
        03
       </month>
       <day>
        07
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="revised">
       <year>
        2020
       </year>
       <month>
        03
       </month>
       <day>
        20
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="accepted">
       <year>
        2020
       </year>
       <month>
        03
       </month>
       <day>
        26
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        16
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        16
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        16
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      aheadofprint
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32294562
      </articleid>
      <articleid idtype="pii">
       S1477-8939(20)30115-0
      </articleid>
      <articleid idtype="doi">
       10.1016/j.tmaid.2020.101646
      </articleid>
      <articleid idtype="pmc">
       PMC7152904
      </articleid>
     </articleidlist>
     <referencelist>
      <reference>
       <citation>
        Biochemistry. 2004 May 4;43(17):4906-12
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         15109248
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Science. 2003 Jun 13;300(5626):1763-7
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         12746549
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        EMBO J. 2002 Jul 1;21(13):3213-24
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         12093723
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Chem Inf Model. 2015 Nov 23;55(11):2324-37
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         26479676
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Int J Infect Dis. 2020 Feb;91:264-266
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         31953166
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Nucleic Acids Res. 2014 Jan;42(Database issue):D336-46
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         24271400
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="Publisher">
     <pmid version="1">
      32292909
     </pmid>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       18
      </day>
     </daterevised>
     <article pubmodel="Print-Electronic">
      <journal>
       <issn issntype="Electronic">
        2590-0986
       </issn>
       <journalissue citedmedium="Internet">
        <pubdate>
         <year>
          2020
         </year>
         <month>
          Apr
         </month>
         <day>
          13
         </day>
        </pubdate>
       </journalissue>
       <title>
        Medicine in drug discovery
       </title>
       <isoabbreviation>
        Med Drug Discov
       </isoabbreviation>
      </journal>
      <articletitle>
       Target Virus or Target Ourselves for COVID-19 Drugs Discovery?-Lessons learned from anti-influenzas virus therapies.
      </articletitle>
      <pagination>
       <medlinepgn>
        100037
       </medlinepgn>
      </pagination>
      <elocationid eidtype="doi" validyn="Y">
       10.1016/j.medidd.2020.100037
      </elocationid>
      <abstract>
       <abstracttext>
        The COVID-19 pandemic, after it was reported in December 2019, is a highly contagious and now spreading to over 190 countries, causing a severe public health burden. Currently, there is no vaccine or specific drug to treat COVID-19, which is caused by a novel coronavirus, SARS-2-CoV. For this emergency, the FDA has approved Remdesivir and Hydroxychloroquine for treatment of COVID-19 as Emergency Use Authorization. However, even after this pandemic, COVID-19 may still have a chance to come back. Therefore, we need to come out with new strategies for drug discovery for combating COVID-19 in the future.
       </abstracttext>
       <copyrightinformation>
        © 2020 Published by Elsevier B.V.
       </copyrightinformation>
      </abstract>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Liao
        </lastname>
        <forename>
         Jiayu
        </forename>
        <initials>
         J
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Bioengineering, Bourns College of Engineering, University of California at Riverside, 900 University Avenue, Riverside, California 92521.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Way
        </lastname>
        <forename>
         George
        </forename>
        <initials>
         G
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Bioengineering, Bourns College of Engineering, University of California at Riverside, 900 University Avenue, Riverside, California 92521.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Madahar
        </lastname>
        <forename>
         Vipul
        </forename>
        <initials>
         V
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Bioengineering, Bourns College of Engineering, University of California at Riverside, 900 University Avenue, Riverside, California 92521.
         </affiliation>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <publicationtypelist>
       <publicationtype ui="D016421">
        Editorial
       </publicationtype>
      </publicationtypelist>
      <articledate datetype="Electronic">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        13
       </day>
      </articledate>
     </article>
     <medlinejournalinfo>
      <country>
       Netherlands
      </country>
      <medlineta>
       Med Drug Discov
      </medlineta>
      <nlmuniqueid>
       101765689
      </nlmuniqueid>
      <issnlinking>
       2590-0986
      </issnlinking>
     </medlinejournalinfo>
     <keywordlist owner="NOTNLM">
      <keyword majortopicyn="N">
       COVID-19
      </keyword>
      <keyword majortopicyn="N">
       Host factor
      </keyword>
      <keyword majortopicyn="N">
       Influenza virus
      </keyword>
      <keyword majortopicyn="N">
       SARS-CoV-2
      </keyword>
      <keyword majortopicyn="N">
       Therapeutics
      </keyword>
      <keyword majortopicyn="N">
       drug discovery
      </keyword>
     </keywordlist>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="received">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        01
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="revised">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        05
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="accepted">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        06
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        16
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        16
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        16
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      aheadofprint
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32292909
      </articleid>
      <articleid idtype="doi">
       10.1016/j.medidd.2020.100037
      </articleid>
      <articleid idtype="pii">
       S2590-0986(20)30024-5
      </articleid>
      <articleid idtype="pii">
       100037
      </articleid>
      <articleid idtype="pmc">
       PMC7153514
      </articleid>
     </articleidlist>
     <?pmcsd ?>
     <referencelist>
      <reference>
       <citation>
        J Virol. 2012 Jan;86(2):642-54
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         22072786
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Antimicrob Agents Chemother. 2006 Jul;50(7):2395-402
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         16801417
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Curr Opin Pharmacol. 2016 Oct;30:106-115
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         27570127
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        RNA Biol. 2011 Mar-Apr;8(2):270-9
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         21593585
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Mol Biosyst. 2012 Jun;8(6):1723-9
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         22466055
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Science. 1997 Dec 5;278(5344):1803-5
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         9388184
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Antimicrob Agents Chemother. 2008 Sep;52(9):3284-92
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         18625765
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Nat Rev Genet. 2008 Apr;9(4):267-76
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         18319742
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        JAMA. 2009 Mar 11;301(10):1034-41
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         19255110
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Virol J. 2010 Mar 05;7:53
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         20202225
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Microb Drug Resist. 2017 Mar;23(2):253-260
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         27203354
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Virology. 2014 Aug;462-463:135-48
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         24971706
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Eur J Pharmacol. 2017 Aug 15;809:178-190
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         28533172
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Antiviral Res. 2014 Oct;110:94-103
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         25108173
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Proc Natl Acad Sci U S A. 1993 May 1;90(9):4171-5
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         8387212
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="Publisher">
     <pmid version="1">
      32292689
     </pmid>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       18
      </day>
     </daterevised>
     <article pubmodel="Print-Electronic">
      <journal>
       <issn issntype="Print">
        2211-3835
       </issn>
       <journalissue citedmedium="Print">
        <pubdate>
         <year>
          2020
         </year>
         <month>
          Feb
         </month>
         <day>
          27
         </day>
        </pubdate>
       </journalissue>
       <title>
        Acta pharmaceutica Sinica. B
       </title>
       <isoabbreviation>
        Acta Pharm Sin B
       </isoabbreviation>
      </journal>
      <articletitle>
       Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods.
      </articletitle>
      <elocationid eidtype="doi" validyn="Y">
       10.1016/j.apsb.2020.02.008
      </elocationid>
      <abstract>
       <abstracttext>
        SARS-CoV-2 has caused tens of thousands of infections and more than one thousand deaths. There are currently no registered therapies for treating coronavirus infections. Because of time consuming process of new drug development, drug repositioning may be the only solution to the epidemic of sudden infectious diseases. We systematically analyzed all the proteins encoded by SARS-CoV-2 genes, compared them with proteins from other coronaviruses, predicted their structures, and built 19 structures that could be done by homology modeling. By performing target-based virtual ligand screening, a total of 21 targets (including two human targets) were screened against compound libraries including ZINC drug database and our own database of natural products. Structure and screening results of important targets such as 3-chymotrypsin-like protease (3CLpro), Spike, RNA-dependent RNA polymerase (RdRp), and papain like protease (PLpro) were discussed in detail. In addition, a database of 78 commonly used anti-viral drugs including those currently on the market and undergoing clinical trials for SARS-CoV-2 was constructed. Possible targets of these compounds and potential drugs acting on a certain target were predicted. This study will provide new lead compounds and targets for further
        <i>
         in vitro
        </i>
        and
        <i>
         in vivo
        </i>
        studies of SARS-CoV-2, new insights for those drugs currently ongoing clinical studies, and also possible new strategies for drug repositioning to treat SARS-CoV-2 infections.
       </abstracttext>
       <copyrightinformation>
        © 2020 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V.
       </copyrightinformation>
      </abstract>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Wu
        </lastname>
        <forename>
         Canrong
        </forename>
        <initials>
         C
        </initials>
        <affiliationinfo>
         <affiliation>
          Hubei Key Laboratory of Natural Medicinal Chemistry and Resource Evaluation, School of Pharmacy, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Liu
        </lastname>
        <forename>
         Yang
        </forename>
        <initials>
         Y
        </initials>
        <affiliationinfo>
         <affiliation>
          Wuya College of Innovation, Key Laboratory of Structure-Based Drug Design &amp; Discovery, Ministry of Education, Shenyang Pharmaceutical University, Shenyang 110016, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Yang
        </lastname>
        <forename>
         Yueying
        </forename>
        <initials>
         Y
        </initials>
        <affiliationinfo>
         <affiliation>
          Wuya College of Innovation, Key Laboratory of Structure-Based Drug Design &amp; Discovery, Ministry of Education, Shenyang Pharmaceutical University, Shenyang 110016, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Zhang
        </lastname>
        <forename>
         Peng
        </forename>
        <initials>
         P
        </initials>
        <affiliationinfo>
         <affiliation>
          Wuya College of Innovation, Key Laboratory of Structure-Based Drug Design &amp; Discovery, Ministry of Education, Shenyang Pharmaceutical University, Shenyang 110016, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Zhong
        </lastname>
        <forename>
         Wu
        </forename>
        <initials>
         W
        </initials>
        <affiliationinfo>
         <affiliation>
          National Engineering Research Center for the Emergency Drug, Beijing Institute of Pharmacology and Toxicology, Beijing 100850, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Wang
        </lastname>
        <forename>
         Yali
        </forename>
        <initials>
         Y
        </initials>
        <affiliationinfo>
         <affiliation>
          Wuya College of Innovation, Key Laboratory of Structure-Based Drug Design &amp; Discovery, Ministry of Education, Shenyang Pharmaceutical University, Shenyang 110016, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Wang
        </lastname>
        <forename>
         Qiqi
        </forename>
        <initials>
         Q
        </initials>
        <affiliationinfo>
         <affiliation>
          Wuya College of Innovation, Key Laboratory of Structure-Based Drug Design &amp; Discovery, Ministry of Education, Shenyang Pharmaceutical University, Shenyang 110016, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Xu
        </lastname>
        <forename>
         Yang
        </forename>
        <initials>
         Y
        </initials>
        <affiliationinfo>
         <affiliation>
          Wuya College of Innovation, Key Laboratory of Structure-Based Drug Design &amp; Discovery, Ministry of Education, Shenyang Pharmaceutical University, Shenyang 110016, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Li
        </lastname>
        <forename>
         Mingxue
        </forename>
        <initials>
         M
        </initials>
        <affiliationinfo>
         <affiliation>
          Wuya College of Innovation, Key Laboratory of Structure-Based Drug Design &amp; Discovery, Ministry of Education, Shenyang Pharmaceutical University, Shenyang 110016, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Li
        </lastname>
        <forename>
         Xingzhou
        </forename>
        <initials>
         X
        </initials>
        <affiliationinfo>
         <affiliation>
          National Engineering Research Center for the Emergency Drug, Beijing Institute of Pharmacology and Toxicology, Beijing 100850, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Zheng
        </lastname>
        <forename>
         Mengzhu
        </forename>
        <initials>
         M
        </initials>
        <affiliationinfo>
         <affiliation>
          Hubei Key Laboratory of Natural Medicinal Chemistry and Resource Evaluation, School of Pharmacy, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Chen
        </lastname>
        <forename>
         Lixia
        </forename>
        <initials>
         L
        </initials>
        <affiliationinfo>
         <affiliation>
          Wuya College of Innovation, Key Laboratory of Structure-Based Drug Design &amp; Discovery, Ministry of Education, Shenyang Pharmaceutical University, Shenyang 110016, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Li
        </lastname>
        <forename>
         Hua
        </forename>
        <initials>
         H
        </initials>
        <affiliationinfo>
         <affiliation>
          Hubei Key Laboratory of Natural Medicinal Chemistry and Resource Evaluation, School of Pharmacy, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          Wuya College of Innovation, Key Laboratory of Structure-Based Drug Design &amp; Discovery, Ministry of Education, Shenyang Pharmaceutical University, Shenyang 110016, China.
         </affiliation>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <publicationtypelist>
       <publicationtype ui="D016428">
        Journal Article
       </publicationtype>
      </publicationtypelist>
      <articledate datetype="Electronic">
       <year>
        2020
       </year>
       <month>
        02
       </month>
       <day>
        27
       </day>
      </articledate>
     </article>
     <medlinejournalinfo>
      <country>
       Netherlands
      </country>
      <medlineta>
       Acta Pharm Sin B
      </medlineta>
      <nlmuniqueid>
       101600560
      </nlmuniqueid>
      <issnlinking>
       2211-3835
      </issnlinking>
     </medlinejournalinfo>
     <keywordlist owner="NOTNLM">
      <keyword majortopicyn="N">
       3CLpro, 3-chymotrypsin-like protease
      </keyword>
      <keyword majortopicyn="N">
       Drug repurposing
      </keyword>
      <keyword majortopicyn="N">
       E, envelope
      </keyword>
      <keyword majortopicyn="N">
       Homology modeling
      </keyword>
      <keyword majortopicyn="N">
       M, membrane protein
      </keyword>
      <keyword majortopicyn="N">
       Molecular docking
      </keyword>
      <keyword majortopicyn="N">
       N, nucleocapsid protein
      </keyword>
      <keyword majortopicyn="N">
       Nsp, non-structure protein
      </keyword>
      <keyword majortopicyn="N">
       ORF, open reading frame
      </keyword>
      <keyword majortopicyn="N">
       PDB, protein data bank
      </keyword>
      <keyword majortopicyn="N">
       RdRp, RNA-dependence RNA polymerase
      </keyword>
      <keyword majortopicyn="N">
       Remdesivir
      </keyword>
      <keyword majortopicyn="N">
       S, Spike
      </keyword>
      <keyword majortopicyn="N">
       SARS-CoV-2
      </keyword>
      <keyword majortopicyn="N">
       SUD, SARS unique domain
      </keyword>
      <keyword majortopicyn="N">
       UB, ubiquitin-like domain
      </keyword>
     </keywordlist>
     <coistatement>
      The authors claim that the researchers in this study have no conflict of interest.
     </coistatement>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="received">
       <year>
        2020
       </year>
       <month>
        02
       </month>
       <day>
        12
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="revised">
       <year>
        2020
       </year>
       <month>
        02
       </month>
       <day>
        17
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="accepted">
       <year>
        2020
       </year>
       <month>
        02
       </month>
       <day>
        18
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        16
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        16
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        16
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      aheadofprint
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32292689
      </articleid>
      <articleid idtype="doi">
       10.1016/j.apsb.2020.02.008
      </articleid>
      <articleid idtype="pii">
       S2211-3835(20)30299-9
      </articleid>
      <articleid idtype="pmc">
       PMC7102550
      </articleid>
     </articleidlist>
     <?pmcsd ?>
     <referencelist>
      <reference>
       <citation>
        Virology. 2006 Jun 20;350(1):15-25
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         16510163
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Comput Aided Mol Des. 2012 Jun;26(6):675-86
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         22569591
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Nature. 2013 Nov 28;503(7477):535-8
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         24172901
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Virus Res. 2015 Apr 16;202:120-34
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         25445340
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Virol. 2016 Jan 20;90(7):3627-39
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         26792741
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Biochem Biophys Res Commun. 2008 Feb 15;366(3):738-44
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         18082623
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        PLoS Biol. 2005 Oct;3(10):e324
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         16128623
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Exp Mol Pathol. 2020 Apr;113:104350
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         31805278
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Viruses. 2012 Apr;4(4):557-80
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         22590686
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Med Chem. 2016 Jul 28;59(14):6595-628
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         26878082
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Virol. 2003 Aug;77(16):8801-11
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         12885899
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Antimicrob Agents Chemother. 2014 Aug;58(8):4885-93
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         24841273
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Lancet Infect Dis. 2013 Oct;13(10):859-66
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         23933067
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Virol. 2015 Dec;89(23):11820-33
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         26378163
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Chembiochem. 2008 Dec 15;9(18):3037-45
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         19031435
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Virol. 2013 Jul;87(14):7790-2
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         23678167
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Clin Microbiol Rev. 2007 Oct;20(4):660-94
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         17934078
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Virol. 2015 Apr;89(7):3659-70
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         25589660
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Virus Res. 2014 Dec 19;194:200-10
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         25451066
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Antivir Chem Chemother. 2006;17(5):285-9
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         17176633
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Chem Inf Model. 2012 Jul 23;52(7):1757-68
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         22587354
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Virol. 2004 Dec;78(24):13600-12
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         15564471
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Virol. 2004 Jul;78(14):7833-8
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         15220459
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        N Engl J Med. 2003 May 15;348(20):1986-94
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         12682352
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Nat Rev Drug Discov. 2016 May;15(5):327-47
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         26868298
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        N Engl J Med. 2012 Nov 8;367(19):1814-20
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         23075143
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Virol. 2008 May;82(9):4471-9
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         18305050
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Nature. 2003 Nov 27;426(6965):450-4
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         14647384
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Virol. 2011 May;85(9):4122-34
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         21325420
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        EMBO J. 2006 Oct 18;25(20):4933-42
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         17024178
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Proc Natl Acad Sci U S A. 2006 Aug 22;103(34):12885-90
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         16912115
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Protein Cell. 2014 May;5(5):369-81
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         24622840
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Biol Chem. 2015 Jan 30;290(5):3172-82
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         25505178
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Proc Natl Acad Sci U S A. 2003 Nov 11;100(23):13190-5
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         14585926
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Antiviral Res. 2014 Jan;101:122-30
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         24269475
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Proc Natl Acad Sci U S A. 2014 Apr 1;111(13):4970-5
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         24599590
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Infect. 2013 Dec;67(6):606-16
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         24096239
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Med Chem. 1999 Mar 11;42(5):791-804
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         10072678
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Proc Natl Acad Sci U S A. 2005 Sep 27;102(39):14040-5
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         16169905
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Science. 2005 Sep 16;309(5742):1864-8
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         16166518
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Lancet Infect Dis. 2014 Nov;14(11):1090-1095
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         25278221
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Nucleic Acids Res. 2005 Jul 1;33(Web Server issue):W284-8
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         15980471
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="PubMed-not-MEDLINE">
     <pmid version="1">
      32284951
     </pmid>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       16
      </day>
     </daterevised>
     <article pubmodel="Electronic-eCollection">
      <journal>
       <issn issntype="Print">
        2328-8957
       </issn>
       <journalissue citedmedium="Print">
        <volume>
         7
        </volume>
        <issue>
         4
        </issue>
        <pubdate>
         <year>
          2020
         </year>
         <month>
          Apr
         </month>
        </pubdate>
       </journalissue>
       <title>
        Open forum infectious diseases
       </title>
       <isoabbreviation>
        Open Forum Infect Dis
       </isoabbreviation>
      </journal>
      <articletitle>
       Coronavirus Disease 2019 Treatment: A Review of Early and Emerging Options.
      </articletitle>
      <pagination>
       <medlinepgn>
        ofaa105
       </medlinepgn>
      </pagination>
      <elocationid eidtype="doi" validyn="Y">
       10.1093/ofid/ofaa105
      </elocationid>
      <abstract>
       <abstracttext>
        Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the cause of coronavirus disease 2019 (COVID-19), has spread across the globe resulting in a pandemic. At the time of this review, COVID-19 has been diagnosed in more than 200 000 patients and associated with over 8000 deaths (Centers for Disease Control and Prevention, World Health Organization). On behalf of the Society of Infectious Diseases Pharmacists, we herein summarize the current evidence as of March 18, 2020 to provide guidance on potential COVID-19 treatment options. It is important to caution readers that new data emerges daily regarding clinical characteristics, treatment options, and outcomes for COVID-19. Optimized supportive care remains the mainstay of therapy, and the clinical efficacy for the subsequent agents is still under investigation. Antimicrobial stewardship programs, including infectious diseases pharmacists and physicians, are at the forefront of COVID-19 emergency preparedness. We encourage all readers to continue to assess clinical data as it emerges and share their experience within our community in a well-controlled, adequately powered fashion.
       </abstracttext>
       <copyrightinformation>
        © The Author(s) 2020. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
       </copyrightinformation>
      </abstract>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         McCreary
        </lastname>
        <forename>
         Erin K
        </forename>
        <initials>
         EK
        </initials>
        <identifier source="ORCID">
         0000-0001-6705-2225
        </identifier>
        <affiliationinfo>
         <affiliation>
          Department of Pharmacy, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Pogue
        </lastname>
        <forename>
         Jason M
        </forename>
        <initials>
         JM
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Clinical Pharmacy, University of Michigan College of Pharmacy, Ann Arbor, Michigan, USA.
         </affiliation>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <publicationtypelist>
       <publicationtype ui="D016428">
        Journal Article
       </publicationtype>
       <publicationtype ui="D016454">
        Review
       </publicationtype>
      </publicationtypelist>
      <articledate datetype="Electronic">
       <year>
        2020
       </year>
       <month>
        03
       </month>
       <day>
        23
       </day>
      </articledate>
     </article>
     <medlinejournalinfo>
      <country>
       United States
      </country>
      <medlineta>
       Open Forum Infect Dis
      </medlineta>
      <nlmuniqueid>
       101637045
      </nlmuniqueid>
      <issnlinking>
       2328-8957
      </issnlinking>
     </medlinejournalinfo>
     <keywordlist owner="NOTNLM">
      <keyword majortopicyn="N">
       COVID-19
      </keyword>
      <keyword majortopicyn="N">
       SARS-CoV-2
      </keyword>
      <keyword majortopicyn="N">
       hydroxychloroquine
      </keyword>
      <keyword majortopicyn="N">
       lopinavir/ritonavir
      </keyword>
      <keyword majortopicyn="N">
       remdesivir
      </keyword>
     </keywordlist>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="received">
       <year>
        2020
       </year>
       <month>
        03
       </month>
       <day>
        18
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="accepted">
       <year>
        2020
       </year>
       <month>
        03
       </month>
       <day>
        23
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        15
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        15
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        15
       </day>
       <hour>
        6
       </hour>
       <minute>
        1
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      epublish
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32284951
      </articleid>
      <articleid idtype="doi">
       10.1093/ofid/ofaa105
      </articleid>
      <articleid idtype="pii">
       ofaa105
      </articleid>
      <articleid idtype="pmc">
       PMC7144823
      </articleid>
     </articleidlist>
     <referencelist>
      <reference>
       <citation>
        Clin Infect Dis. 2019 Nov 13;69(11):1903-1911
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         30753384
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Clin Pharmacokinet. 1993 Nov;25(5):392-407
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         7904547
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Am J Respir Crit Care Med. 2018 Mar 15;197(6):757-767
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         29161116
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Clin Virol. 2004 Dec;31(4):304-9
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         15494274
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Hong Kong Med J. 2003 Dec;9(6):399-406
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         14660806
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Virol. 2010 Mar;84(5):2511-21
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         20032190
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        JAMA. 2003 Jun 4;289(21):2801-9
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         12734147
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Biosci Trends. 2020 Mar 16;14(1):64-68
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32037389
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Antiviral Res. 2020 Mar 5;177:104762
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32147496
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Trials. 2020 Jan 3;21(1):8
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         31900204
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Infect. 2005 Aug;51(2):98-102
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         16038758
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Crit Care Med. 2019 Sep;47(9):e735-e743
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         31162191
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Cell Res. 2020 Mar;30(3):269-271
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32020029
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        JAMA. 2020 Mar 3;:
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32125362
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Infect Dis. 2015 Dec 15;212(12):1904-13
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         26198719
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Lancet. 2020 Feb 29;395(10225):683-684
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32122468
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Sci Transl Med. 2017 Jun 28;9(396):
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         28659436
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        PLoS Med. 2006 Sep;3(9):e343
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         16968120
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Lancet. 2020 Mar 28;395(10229):1054-1062
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32171076
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        N Engl J Med. 2003 May 15;348(20):1986-94
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         12682352
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Oncologist. 2018 Aug;23(8):943-947
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         29622697
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Biosci Trends. 2020 Mar 16;14(1):72-73
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32074550
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Lancet. 2020 Feb 15;395(10223):e30-e31
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32032529
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Expert Rev Clin Immunol. 2019 Aug;15(8):813-822
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         31219357
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Int J Antimicrob Agents. 2020 Mar 20;:105949
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32205204
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        JAMA Intern Med. 2020 Mar 13;:
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32167524
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Thorax. 2004 Mar;59(3):252-6
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         14985565
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Korean Med Sci. 2020 Feb 17;35(6):e79
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32056407
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Med Chem. 2017 Mar 9;60(5):1648-1661
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         28124907
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Life Sci. 2020 May 1;248:117477
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32119961
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        N Engl J Med. 2020 Mar 5;382(10):929-936
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32004427
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Lancet Infect Dis. 2014 Jul;14(7):609-18
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         24852376
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Clin Infect Dis. 2020 Mar 09;:
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32150618
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        mBio. 2018 Mar 6;9(2):
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         29511076
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Infect Public Health. 2016 May-Jun;9(3):227-30
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         27095301
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Infect Dis. 2017 Jan 15;215(2):171-174
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         28073857
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        ACS Infect Dis. 2020 Mar 10;:
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32125140
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Acquir Immune Defic Syndr. 2011 Dec 1;58(4):385-91
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         21876444
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Clin Infect Dis. 2018 Aug 1;67(4):533-540
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         29481659
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        N Engl J Med. 2019 Dec 12;381(24):2293-2303
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         31774950
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Biol Chem. 2020 Apr 10;295(15):4773-4779
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32094225
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Lancet Infect Dis. 2020 Apr;20(4):398-400
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32113510
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Clin Infect Dis. 2020 Apr 15;70(9):1837-1844
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         31925415
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Med Virol. 2020 May;92(5):461-463
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32073161
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Ther Drug Monit. 2011 Oct;33(5):573-82
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         21912331
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        JAMA. 2020 Feb 7;:
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32031570
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Nature. 2016 Mar 17;531(7594):381-5
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         26934220
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Nat Commun. 2020 Jan 10;11(1):222
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         31924756
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Emerg Infect Dis. 2004 Apr;10(4):581-6
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         15200845
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Lancet. 2020 Feb 15;395(10223):497-506
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         31986264
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        N Engl J Med. 2020 Mar 18;:
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32187464
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Biol Blood Marrow Transplant. 2019 Apr;25(4):625-638
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         30592986
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Proc Natl Acad Sci U S A. 2008 Oct 21;105(42):16119-24
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         18852458
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Antimicrob Agents Chemother. 2014 Aug;58(8):4875-84
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         24841269
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Lancet. 2020 Feb 15;395(10223):507-513
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32007143
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Int J Antimicrob Agents. 2020 Mar 4;:105932
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32145363
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Lancet. 2016 Jul 30;388(10043):498-503
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         27209148
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Antiviral Res. 2018 Feb;150:155-163
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         29289665
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Med Chem. 2006 May 4;49(9):2845-9
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         16640347
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Infect Control Hosp Epidemiol. 2020 Mar 13;:1-2
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32167442
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Chest. 2006 Jun;129(6):1441-52
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         16778260
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="Publisher">
     <pmid version="1">
      32284326
     </pmid>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       16
      </day>
     </daterevised>
     <article pubmodel="Print-Electronic">
      <journal>
       <issn issntype="Electronic">
        1083-351X
       </issn>
       <journalissue citedmedium="Internet">
        <pubdate>
         <year>
          2020
         </year>
         <month>
          Apr
         </month>
         <day>
          13
         </day>
        </pubdate>
       </journalissue>
       <title>
        The Journal of biological chemistry
       </title>
       <isoabbreviation>
        J. Biol. Chem.
       </isoabbreviation>
      </journal>
      <articletitle>
       Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency.
      </articletitle>
      <elocationid eidtype="pii" validyn="Y">
       jbc.RA120.013679
      </elocationid>
      <elocationid eidtype="doi" validyn="Y">
       10.1074/jbc.RA120.013679
      </elocationid>
      <abstract>
       <abstracttext>
        Effective treatments for coronavirus disease 2019 (COVID-19) are urgently needed to control this current pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Replication of SARS-CoV-2 depends on the viral RNA-dependent RNA polymerase (RdRp), which is the likely target of the investigational nucleotide analogue remdesivir (RDV). RDV shows broad-spectrum antiviral activity against RNA viruses, and previous studies with RdRps from Ebola virus (EBOV) and Middle East respiratory syndrome coronavirus (MERS-CoV) have revealed that delayed chain-termination is RDV's plausible mechanism of action. Here, we expressed and purified active SARS-CoV-2 RdRp composed of the non-structural proteins nsp8 and nsp12. Enzyme kinetics indicated that this RdRp efficiently incorporates the active triphosphate form of RDV (RDV-TP) into RNA. Incorporation of RDV-TP at position i caused termination of RNA synthesis at position i+3. We obtained almost identical results with SARS-CoV, MERS-CoV, and SARS-CoV-2 RdRps. A unique property of RDV-TP is its high selectivity over incorporation of its natural nucleotide counterpart ATP. In this regard, the triphosphate forms of 2'-C-methylated compounds, including sofosbuvir, approved for the management of hepatitis C virus infection, and the broad-acting antivirals favipiravir and ribavirin, exhibited significant deficits. Furthermore, we provide evidence for the target specificity of RDV, as RDV-TP was less efficiently incorporated by the distantly related Lassa virus RdRp, and termination of RNA synthesis was not observed. These results collectively provide a unifying, refined mechanism of RDV-mediated RNA synthesis inhibition in coronaviruses and define this nucleotide analogue as a direct-acting antiviral (DAA).
       </abstracttext>
       <copyrightinformation>
        Published under license by The American Society for Biochemistry and Molecular Biology, Inc.
       </copyrightinformation>
      </abstract>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Gordon
        </lastname>
        <forename>
         Calvin J
        </forename>
        <initials>
         CJ
        </initials>
        <affiliationinfo>
         <affiliation>
          University of Alberta, Canada.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Tchesnokov
        </lastname>
        <forename>
         Egor P
        </forename>
        <initials>
         EP
        </initials>
        <identifier source="ORCID">
         https://orcid.org/0000-0003-1698-2961
        </identifier>
        <affiliationinfo>
         <affiliation>
          University of Alberta, Canada.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Woolner
        </lastname>
        <forename>
         Emma
        </forename>
        <initials>
         E
        </initials>
        <identifier source="ORCID">
         https://orcid.org/0000-0002-8697-7802
        </identifier>
        <affiliationinfo>
         <affiliation>
          University of Alberta, Canada.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Perry
        </lastname>
        <forename>
         Jason K
        </forename>
        <initials>
         JK
        </initials>
        <identifier source="ORCID">
         https://orcid.org/0000-0001-5492-0652
        </identifier>
        <affiliationinfo>
         <affiliation>
          Gilead Sciences, Inc, United States.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Feng
        </lastname>
        <forename>
         Joy Y
        </forename>
        <initials>
         JY
        </initials>
        <affiliationinfo>
         <affiliation>
          Biology, Gilead Sciences, Inc., United States.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Porter
        </lastname>
        <forename>
         Danielle P
        </forename>
        <initials>
         DP
        </initials>
        <affiliationinfo>
         <affiliation>
          Gilead Scienes, Inc., United States.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Gotte
        </lastname>
        <forename>
         Matthias
        </forename>
        <initials>
         M
        </initials>
        <affiliationinfo>
         <affiliation>
          Medical Microbiology and Immunology, University of Alberta, Canada.
         </affiliation>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <publicationtypelist>
       <publicationtype ui="D016428">
        Journal Article
       </publicationtype>
      </publicationtypelist>
      <articledate datetype="Electronic">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        13
       </day>
      </articledate>
     </article>
     <medlinejournalinfo>
      <country>
       United States
      </country>
      <medlineta>
       J Biol Chem
      </medlineta>
      <nlmuniqueid>
       2985121R
      </nlmuniqueid>
      <issnlinking>
       0021-9258
      </issnlinking>
     </medlinejournalinfo>
     <citationsubset>
      IM
     </citationsubset>
     <keywordlist owner="NOTNLM">
      <keyword majortopicyn="N">
       RNA polymerase
      </keyword>
      <keyword majortopicyn="N">
       drug action
      </keyword>
      <keyword majortopicyn="N">
       drug development
      </keyword>
      <keyword majortopicyn="N">
       drug discovery
      </keyword>
      <keyword majortopicyn="N">
       plus-stranded RNA virus
      </keyword>
     </keywordlist>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="accepted">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        13
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="received">
       <year>
        2020
       </year>
       <month>
        03
       </month>
       <day>
        30
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        15
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        15
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        15
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      aheadofprint
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32284326
      </articleid>
      <articleid idtype="pii">
       RA120.013679
      </articleid>
      <articleid idtype="doi">
       10.1074/jbc.RA120.013679
      </articleid>
     </articleidlist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="Publisher">
     <pmid version="1">
      32283108
     </pmid>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       17
      </day>
     </daterevised>
     <article pubmodel="Print-Electronic">
      <journal>
       <issn issntype="Electronic">
        1872-9096
       </issn>
       <journalissue citedmedium="Internet">
        <volume>
         178
        </volume>
        <pubdate>
         <year>
          2020
         </year>
         <month>
          Apr
         </month>
         <day>
          10
         </day>
        </pubdate>
       </journalissue>
       <title>
        Antiviral research
       </title>
       <isoabbreviation>
        Antiviral Res.
       </isoabbreviation>
      </journal>
      <articletitle>
       Remdesivir and SARS-CoV-2: Structural requirements at both nsp12 RdRp and nsp14 Exonuclease active-sites.
      </articletitle>
      <pagination>
       <medlinepgn>
        104793
       </medlinepgn>
      </pagination>
      <elocationid eidtype="pii" validyn="Y">
       S0166-3542(20)30207-2
      </elocationid>
      <elocationid eidtype="doi" validyn="Y">
       10.1016/j.antiviral.2020.104793
      </elocationid>
      <abstract>
       <abstracttext>
        The rapid global emergence of SARS-CoV-2 has been the cause of significant health concern, highlighting the immediate need for antivirals. Viral RNA-dependent RNA polymerases (RdRp) play essential roles in viral RNA synthesis, and thus remains the target of choice for the prophylactic or curative treatment of several viral diseases, due to high sequence and structural conservation. To date, the most promising broad-spectrum class of viral RdRp inhibitors are nucleoside analogues (NAs), with over 25 approved for the treatment of several medically important viral diseases. However, Coronaviruses stand out as a particularly challenging case for NA drug design due to the presence of an exonuclease (ExoN) domain capable of excising incorporated NAs and thus providing resistance to many of these available antivirals. Here we use the available structures of the SARS-CoV RdRp and ExoN proteins, as well as Lassa virus N exonuclease to derive models of catalytically competent SARS-CoV-2 enzymes. We then map a promising NA candidate, GS-441524 (the active metabolite of Remdesivir) to the nucleoside active site of both proteins, identifying the residues important for nucleotide recognition, discrimination, and excision. Interestingly, GS-441524 addresses both enzyme active sites in a manner consistent with significant incorporation, delayed chain termination, and altered excision due to the ribose 1'-CN group, which may account for the increased antiviral effect compared to other available analogues. Additionally, we propose structural and function implications of two previously identified RdRp resistance mutations in relation to resistance against Remdesivir. This study highlights the importance of considering the balance between incorporation and excision properties of NAs between the RdRp and ExoN.
       </abstracttext>
       <copyrightinformation>
        Copyright © 2020 Elsevier B.V. All rights reserved.
       </copyrightinformation>
      </abstract>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Shannon
        </lastname>
        <forename>
         Ashleigh
        </forename>
        <initials>
         A
        </initials>
        <affiliationinfo>
         <affiliation>
          Aix-Marseille Université, CNRS UMR 7257, Architecture et Fonction des Macromolécules Biologiques, 163 Avenue de Luminy, 13288, Marseille, France.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Le
        </lastname>
        <forename>
         Nhung Thi-Tuyet
        </forename>
        <initials>
         NT
        </initials>
        <affiliationinfo>
         <affiliation>
          Aix-Marseille Université, CNRS UMR 7257, Architecture et Fonction des Macromolécules Biologiques, 163 Avenue de Luminy, 13288, Marseille, France.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Selisko
        </lastname>
        <forename>
         Barbara
        </forename>
        <initials>
         B
        </initials>
        <affiliationinfo>
         <affiliation>
          Aix-Marseille Université, CNRS UMR 7257, Architecture et Fonction des Macromolécules Biologiques, 163 Avenue de Luminy, 13288, Marseille, France.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Eydoux
        </lastname>
        <forename>
         Cecilia
        </forename>
        <initials>
         C
        </initials>
        <affiliationinfo>
         <affiliation>
          Aix-Marseille Université, CNRS UMR 7257, Architecture et Fonction des Macromolécules Biologiques, 163 Avenue de Luminy, 13288, Marseille, France.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Alvarez
        </lastname>
        <forename>
         Karine
        </forename>
        <initials>
         K
        </initials>
        <affiliationinfo>
         <affiliation>
          Aix-Marseille Université, CNRS UMR 7257, Architecture et Fonction des Macromolécules Biologiques, 163 Avenue de Luminy, 13288, Marseille, France.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Guillemot
        </lastname>
        <forename>
         Jean-Claude
        </forename>
        <initials>
         JC
        </initials>
        <affiliationinfo>
         <affiliation>
          Aix-Marseille Université, CNRS UMR 7257, Architecture et Fonction des Macromolécules Biologiques, 163 Avenue de Luminy, 13288, Marseille, France.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Decroly
        </lastname>
        <forename>
         Etienne
        </forename>
        <initials>
         E
        </initials>
        <affiliationinfo>
         <affiliation>
          Aix-Marseille Université, CNRS UMR 7257, Architecture et Fonction des Macromolécules Biologiques, 163 Avenue de Luminy, 13288, Marseille, France.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Peersen
        </lastname>
        <forename>
         Olve
        </forename>
        <initials>
         O
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Biochemistry and Molecular Biology, Colorado State University, Fort Collins, CO, USA; Aix-Marseille Université, CNRS UMR 7257, Architecture et Fonction des Macromolécules Biologiques, 163 Avenue de Luminy, 13288, Marseille, France.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Ferron
        </lastname>
        <forename>
         Francois
        </forename>
        <initials>
         F
        </initials>
        <affiliationinfo>
         <affiliation>
          Aix-Marseille Université, CNRS UMR 7257, Architecture et Fonction des Macromolécules Biologiques, 163 Avenue de Luminy, 13288, Marseille, France. Electronic address: francois.ferron@afmb.univ-mrs.fr.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Canard
        </lastname>
        <forename>
         Bruno
        </forename>
        <initials>
         B
        </initials>
        <affiliationinfo>
         <affiliation>
          Aix-Marseille Université, CNRS UMR 7257, Architecture et Fonction des Macromolécules Biologiques, 163 Avenue de Luminy, 13288, Marseille, France. Electronic address: bruno.canard@afmb.univ-mrs.fr.
         </affiliation>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <publicationtypelist>
       <publicationtype ui="D016428">
        Journal Article
       </publicationtype>
      </publicationtypelist>
      <articledate datetype="Electronic">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        10
       </day>
      </articledate>
     </article>
     <medlinejournalinfo>
      <country>
       Netherlands
      </country>
      <medlineta>
       Antiviral Res
      </medlineta>
      <nlmuniqueid>
       8109699
      </nlmuniqueid>
      <issnlinking>
       0166-3542
      </issnlinking>
     </medlinejournalinfo>
     <citationsubset>
      IM
     </citationsubset>
     <keywordlist owner="NOTNLM">
      <keyword majortopicyn="N">
       COVID-19
      </keyword>
      <keyword majortopicyn="N">
       Coronavirus
      </keyword>
      <keyword majortopicyn="N">
       Exonuclease
      </keyword>
      <keyword majortopicyn="N">
       Mutation
      </keyword>
      <keyword majortopicyn="N">
       Nucleotide analogue
      </keyword>
      <keyword majortopicyn="N">
       RNA-Dependent RNA polymerase
      </keyword>
      <keyword majortopicyn="N">
       Remdesivir
      </keyword>
      <keyword majortopicyn="N">
       Resistance
      </keyword>
     </keywordlist>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="received">
       <year>
        2020
       </year>
       <month>
        03
       </month>
       <day>
        27
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="revised">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        03
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="accepted">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        05
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        14
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        14
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        14
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      aheadofprint
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32283108
      </articleid>
      <articleid idtype="pii">
       S0166-3542(20)30207-2
      </articleid>
      <articleid idtype="doi">
       10.1016/j.antiviral.2020.104793
      </articleid>
      <articleid idtype="pmc">
       PMC7151495
      </articleid>
     </articleidlist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="Publisher">
     <pmid version="1">
      32282502
     </pmid>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       13
      </day>
     </daterevised>
     <article pubmodel="Print-Electronic">
      <journal>
       <issn issntype="Electronic">
        1533-4023
       </issn>
       <journalissue citedmedium="Internet">
        <pubdate>
         <year>
          2020
         </year>
         <month>
          Apr
         </month>
         <day>
          02
         </day>
        </pubdate>
       </journalissue>
       <title>
        Journal of cardiovascular pharmacology
       </title>
       <isoabbreviation>
        J. Cardiovasc. Pharmacol.
       </isoabbreviation>
      </journal>
      <articletitle>
       Cardiovascular Considerations in Treating Patients with Coronavirus (COVID-19).
      </articletitle>
      <elocationid eidtype="doi" validyn="Y">
       10.1097/FJC.0000000000000836
      </elocationid>
      <abstract>
       <abstracttext>
        A novel betacoronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has spread rapidly across the globe since December 2019. Coronavirus disease 2019 (COVID-19) has a significantly higher mortality rate than seasonal influenza and has disproportionately affected older adults, especially those with cardiovascular disease and related risk factors. Adverse cardiovascular sequalae, such has myocarditis, acute myocardial infarction, and heart failure, have been reported in patients with COVID-19. No established treatment is currently available; however, several therapies, including remdesivir, hydroxychloroquine and chloroquine, and interleukin (IL)-6 inhibitors, are being used off-label and evaluated in ongoing clinical trials. Considering these therapies are not familiar to cardiovascular clinicians managing these patients, this review describes the pharmacology of these therapies in the context of their use in patients with cardiovascular-related conditions.
       </abstracttext>
      </abstract>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Dixon
        </lastname>
        <forename>
         Dave L
        </forename>
        <initials>
         DL
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Pharmacotherapy &amp; Outcomes Science, Virginia Commonwealth University School of Pharmacy, Richmond, Virginia, USA.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          Pauley Heart Center, Division of Cardiology, Department of Internal Medicine, Virginia Commonwealth University, Richmond, Virginia, USA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Van Tassell
        </lastname>
        <forename>
         Benjamin W
        </forename>
        <initials>
         BW
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Pharmacotherapy &amp; Outcomes Science, Virginia Commonwealth University School of Pharmacy, Richmond, Virginia, USA.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          Pauley Heart Center, Division of Cardiology, Department of Internal Medicine, Virginia Commonwealth University, Richmond, Virginia, USA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Vecchié
        </lastname>
        <forename>
         Alessandra
        </forename>
        <initials>
         A
        </initials>
        <affiliationinfo>
         <affiliation>
          Pauley Heart Center, Division of Cardiology, Department of Internal Medicine, Virginia Commonwealth University, Richmond, Virginia, USA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Bonaventura
        </lastname>
        <forename>
         Aldo
        </forename>
        <initials>
         A
        </initials>
        <affiliationinfo>
         <affiliation>
          Pauley Heart Center, Division of Cardiology, Department of Internal Medicine, Virginia Commonwealth University, Richmond, Virginia, USA.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          First Clinic of Internal Medicine, Department of Internal Medicine, University of Genoa, Genoa, Italy.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Talasaz
        </lastname>
        <forename>
         Azita
        </forename>
        <initials>
         A
        </initials>
        <affiliationinfo>
         <affiliation>
          Tehran Heart Center, Tehran Province, Iran.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Kakavand
        </lastname>
        <forename>
         Hesam
        </forename>
        <initials>
         H
        </initials>
        <affiliationinfo>
         <affiliation>
          Tehran Heart Center, Tehran Province, Iran.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         D'Ascenzo
        </lastname>
        <forename>
         Fabrizio
        </forename>
        <initials>
         F
        </initials>
        <affiliationinfo>
         <affiliation>
          Division of Cardiology, Department of Medical Science.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Perciaccante
        </lastname>
        <forename>
         Antonio
        </forename>
        <initials>
         A
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Medicine, University Health Agency Giuliano Isontina, 'San Giovanni di Dio' Hospital, Gorizia, Italy.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Castagno
        </lastname>
        <forename>
         Davide
        </forename>
        <initials>
         D
        </initials>
        <affiliationinfo>
         <affiliation>
          Division of Cardiology, Department of Medical Sciences, University of Turin, Turin, Italy.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Ammirati
        </lastname>
        <forename>
         Enrico
        </forename>
        <initials>
         E
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Cardiology, Niguarda Hospital, Milan, Italy.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Biondi-Zoccai
        </lastname>
        <forename>
         Giuseppe
        </forename>
        <initials>
         G
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Medico-Surgical Sciences and Biotechnologies Sapienza', University of Rome, Rome, Italy.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          Mediterranea Cardiocentro, Napoli, Italy.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Stevens
        </lastname>
        <forename>
         Michael
        </forename>
        <initials>
         M
        </initials>
        <affiliationinfo>
         <affiliation>
          Division of Infectious Diseases, Department of Internal Medicine, Virginia Commonwealth University, Richmond, Virginia, USA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Abbate
        </lastname>
        <forename>
         Antonio
        </forename>
        <initials>
         A
        </initials>
        <affiliationinfo>
         <affiliation>
          Pauley Heart Center, Division of Cardiology, Department of Internal Medicine, Virginia Commonwealth University, Richmond, Virginia, USA.
         </affiliation>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <publicationtypelist>
       <publicationtype ui="D016428">
        Journal Article
       </publicationtype>
      </publicationtypelist>
      <articledate datetype="Electronic">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        02
       </day>
      </articledate>
     </article>
     <medlinejournalinfo>
      <country>
       United States
      </country>
      <medlineta>
       J Cardiovasc Pharmacol
      </medlineta>
      <nlmuniqueid>
       7902492
      </nlmuniqueid>
      <issnlinking>
       0160-2446
      </issnlinking>
     </medlinejournalinfo>
     <citationsubset>
      IM
     </citationsubset>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        14
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        14
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        14
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      aheadofprint
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32282502
      </articleid>
      <articleid idtype="doi">
       10.1097/FJC.0000000000000836
      </articleid>
     </articleidlist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="Publisher">
     <pmid version="1">
      32282022
     </pmid>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       13
      </day>
     </daterevised>
     <article pubmodel="Print-Electronic">
      <journal>
       <issn issntype="Electronic">
        1538-3598
       </issn>
       <journalissue citedmedium="Internet">
        <pubdate>
         <year>
          2020
         </year>
         <month>
          Apr
         </month>
         <day>
          13
         </day>
        </pubdate>
       </journalissue>
       <title>
        JAMA
       </title>
       <isoabbreviation>
        JAMA
       </isoabbreviation>
      </journal>
      <articletitle>
       Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review.
      </articletitle>
      <elocationid eidtype="doi" validyn="Y">
       10.1001/jama.2020.6019
      </elocationid>
      <abstract>
       <abstracttext label="Importance" nlmcategory="UNASSIGNED">
        The pandemic of coronavirus disease 2019 (COVID-19) caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) presents an unprecedented challenge to identify effective drugs for prevention and treatment. Given the rapid pace of scientific discovery and clinical data generated by the large number of people rapidly infected by SARS-CoV-2, clinicians need accurate evidence regarding effective medical treatments for this infection.
       </abstracttext>
       <abstracttext label="Observations" nlmcategory="UNASSIGNED">
        No proven effective therapies for this virus currently exist. The rapidly expanding knowledge regarding SARS-CoV-2 virology provides a significant number of potential drug targets. The most promising therapy is remdesivir. Remdesivir has potent in vitro activity against SARS-CoV-2, but it is not US Food and Drug Administration approved and currently is being tested in ongoing randomized trials. Oseltamivir has not been shown to have efficacy, and corticosteroids are currently not recommended. Current clinical evidence does not support stopping angiotensin-converting enzyme inhibitors or angiotensin receptor blockers in patients with COVID-19.
       </abstracttext>
       <abstracttext label="Conclusions and Relevance" nlmcategory="UNASSIGNED">
        The COVID-19 pandemic represents the greatest global public health crisis of this generation and, potentially, since the pandemic influenza outbreak of 1918. The speed and volume of clinical trials launched to investigate potential therapies for COVID-19 highlight both the need and capability to produce high-quality evidence even in the middle of a pandemic. No therapies have been shown effective to date.
       </abstracttext>
      </abstract>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Sanders
        </lastname>
        <forename>
         James M
        </forename>
        <initials>
         JM
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Pharmacy, University of Texas Southwestern Medical Center, Dallas.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          Division of Infectious Diseases and Geographic Medicine, Department of Medicine, University of Texas Southwestern Medical Center, Dallas.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Monogue
        </lastname>
        <forename>
         Marguerite L
        </forename>
        <initials>
         ML
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Pharmacy, University of Texas Southwestern Medical Center, Dallas.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          Division of Infectious Diseases and Geographic Medicine, Department of Medicine, University of Texas Southwestern Medical Center, Dallas.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Jodlowski
        </lastname>
        <forename>
         Tomasz Z
        </forename>
        <initials>
         TZ
        </initials>
        <affiliationinfo>
         <affiliation>
          Pharmacy Service, VA North Texas Health Care System, Dallas.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Cutrell
        </lastname>
        <forename>
         James B
        </forename>
        <initials>
         JB
        </initials>
        <affiliationinfo>
         <affiliation>
          Division of Infectious Diseases and Geographic Medicine, Department of Medicine, University of Texas Southwestern Medical Center, Dallas.
         </affiliation>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <publicationtypelist>
       <publicationtype ui="D016428">
        Journal Article
       </publicationtype>
      </publicationtypelist>
      <articledate datetype="Electronic">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        13
       </day>
      </articledate>
     </article>
     <medlinejournalinfo>
      <country>
       United States
      </country>
      <medlineta>
       JAMA
      </medlineta>
      <nlmuniqueid>
       7501160
      </nlmuniqueid>
      <issnlinking>
       0098-7484
      </issnlinking>
     </medlinejournalinfo>
     <citationsubset>
      AIM
     </citationsubset>
     <citationsubset>
      IM
     </citationsubset>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        14
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        14
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        14
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      aheadofprint
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32282022
      </articleid>
      <articleid idtype="pii">
       2764727
      </articleid>
      <articleid idtype="doi">
       10.1001/jama.2020.6019
      </articleid>
     </articleidlist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="Publisher">
     <pmid version="1">
      32281114
     </pmid>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       13
      </day>
     </daterevised>
     <article pubmodel="Print-Electronic">
      <journal>
       <issn issntype="Electronic">
        1875-9114
       </issn>
       <journalissue citedmedium="Internet">
        <pubdate>
         <year>
          2020
         </year>
         <month>
          Apr
         </month>
         <day>
          13
         </day>
        </pubdate>
       </journalissue>
       <title>
        Pharmacotherapy
       </title>
       <isoabbreviation>
        Pharmacotherapy
       </isoabbreviation>
      </journal>
      <articletitle>
       Delayed Initiation of Remdesivir in a COVID-19 Positive Patient.
      </articletitle>
      <elocationid eidtype="doi" validyn="Y">
       10.1002/phar.2403
      </elocationid>
      <abstract>
       <abstracttext>
        A case of late initiation of remdesivir antiviral therapy in the successful treatment of a patient with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in a mixed medical ICU of a community teaching hospital is presented. A previously healthy 40 year-old male was admitted to the hospital three days after the onset of coronavirus disease 2019 (COVID-19) symptoms, including dry cough, fever, and shortness of breath progressing to intubation and increased mechanical ventilator support. A request for compassionate use remdesivir was submitted on the same hospital day as the positive COVID-19 PCR result. Supportive measures, in addition to a 5-day course of hydroxychloroquine, were maintained until remdesivir could be supplied on day 9 of hospitalization, 13 days after symptom onset. Sixty hours after initiating remdesivir, the patient was successfully extubated and was able to transition to room air within 24 hours of extubation. Late initiation of remdesivir may be effective in treating SARS-CoV-2, unlike antivirals utilized for different disease states, such as oseltamivir, which are most effective when started as soon as possible following symptom onset. Urgent action is needed by regulatory agencies to work with drug manufacturers to expedite the study and approval of investigational agents targeting SARS-CoV-2 as well as to meet manufacturing demands.
       </abstracttext>
       <copyrightinformation>
        This article is protected by copyright. All rights reserved.
       </copyrightinformation>
      </abstract>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Hillaker
        </lastname>
        <forename>
         Emily
        </forename>
        <initials>
         E
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Family Practice Education, Mercy Health Saint Mary's Grand Rapids, Grand Rapids, MI, USA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Belfer
        </lastname>
        <forename>
         Julie J
        </forename>
        <initials>
         JJ
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Pharmacy Services, Mercy Health Saint Mary's, Grand Rapids, MI, USA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Bondici
        </lastname>
        <forename>
         Anamaria
        </forename>
        <initials>
         A
        </initials>
        <affiliationinfo>
         <affiliation>
          Division of Infectious Diseases, Mercy Health Saint Mary's, Grand Rapids, MI, USA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Murad
        </lastname>
        <forename>
         Hani
        </forename>
        <initials>
         H
        </initials>
        <affiliationinfo>
         <affiliation>
          Division of Critical Care, Mercy Health Saint Mary's, Grand Rapids, MI, USA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Dumkow
        </lastname>
        <forename>
         Lisa E
        </forename>
        <initials>
         LE
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Pharmacy Services, Mercy Health Saint Mary's, Grand Rapids, MI, USA.
         </affiliation>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <publicationtypelist>
       <publicationtype ui="D002363">
        Case Reports
       </publicationtype>
      </publicationtypelist>
      <articledate datetype="Electronic">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        13
       </day>
      </articledate>
     </article>
     <medlinejournalinfo>
      <country>
       United States
      </country>
      <medlineta>
       Pharmacotherapy
      </medlineta>
      <nlmuniqueid>
       8111305
      </nlmuniqueid>
      <issnlinking>
       0277-0008
      </issnlinking>
     </medlinejournalinfo>
     <citationsubset>
      IM
     </citationsubset>
     <keywordlist owner="NOTNLM">
      <keyword majortopicyn="N">
       COVID-19
      </keyword>
      <keyword majortopicyn="N">
       SARS-CoV-2
      </keyword>
      <keyword majortopicyn="N">
       coronavirus
      </keyword>
      <keyword majortopicyn="N">
       pneumonia
      </keyword>
      <keyword majortopicyn="N">
       remdesivir
      </keyword>
      <keyword majortopicyn="N">
       viral pneumonia
      </keyword>
     </keywordlist>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        14
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        14
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        14
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      aheadofprint
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32281114
      </articleid>
      <articleid idtype="doi">
       10.1002/phar.2403
      </articleid>
     </articleidlist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="PubMed-not-MEDLINE">
     <pmid version="1">
      32280433
     </pmid>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       17
      </day>
     </daterevised>
     <article pubmodel="Electronic-eCollection">
      <journal>
       <issn issntype="Print">
        2001-0370
       </issn>
       <journalissue citedmedium="Print">
        <volume>
         18
        </volume>
        <pubdate>
         <year>
          2020
         </year>
        </pubdate>
       </journalissue>
       <title>
        Computational and structural biotechnology journal
       </title>
       <isoabbreviation>
        Comput Struct Biotechnol J
       </isoabbreviation>
      </journal>
      <articletitle>
       Predicting commercially available antiviral drugs that may act on the novel coronavirus (SARS-CoV-2) through a drug-target interaction deep learning model.
      </articletitle>
      <pagination>
       <medlinepgn>
        784-790
       </medlinepgn>
      </pagination>
      <elocationid eidtype="doi" validyn="Y">
       10.1016/j.csbj.2020.03.025
      </elocationid>
      <abstract>
       <abstracttext>
        The infection of a novel coronavirus found in Wuhan of China (SARS-CoV-2) is rapidly spreading, and the incidence rate is increasing worldwide. Due to the lack of effective treatment options for SARS-CoV-2, various strategies are being tested in China, including drug repurposing. In this study, we used our pre-trained deep learning-based drug-target interaction model called Molecule Transformer-Drug Target Interaction (MT-DTI) to identify commercially available drugs that could act on viral proteins of SARS-CoV-2. The result showed that atazanavir, an antiretroviral medication used to treat and prevent the human immunodeficiency virus (HIV), is the best chemical compound, showing an inhibitory potency with
        <i>
         K
         <sub>
          d
         </sub>
        </i>
        of 94.94 nM against the SARS-CoV-2 3C-like proteinase, followed by remdesivir (113.13 nM), efavirenz (199.17 nM), ritonavir (204.05 nM), and dolutegravir (336.91 nM). Interestingly, lopinavir, ritonavir, and darunavir are all designed to target viral proteinases. However, in our prediction, they may also bind to the replication complex components of SARS-CoV-2 with an inhibitory potency with
        <i>
         K
         <sub>
          d
         </sub>
        </i>
        &lt; 1000 nM. In addition, we also found that several antiviral agents, such as Kaletra (lopinavir/ritonavir), could be used for the treatment of SARS-CoV-2. Overall, we suggest that the list of antiviral drugs identified by the MT-DTI model should be considered, when establishing effective treatment strategies for SARS-CoV-2.
       </abstracttext>
       <copyrightinformation>
        © 2020 The Authors.
       </copyrightinformation>
      </abstract>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Beck
        </lastname>
        <forename>
         Bo Ram
        </forename>
        <initials>
         BR
        </initials>
        <affiliationinfo>
         <affiliation>
          Deargen, Inc., Daejeon, Republic of Korea.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Shin
        </lastname>
        <forename>
         Bonggun
        </forename>
        <initials>
         B
        </initials>
        <affiliationinfo>
         <affiliation>
          Deargen, Inc., Daejeon, Republic of Korea.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          Department of Computer Science, Emory University, Atlanta, GA, United States.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Choi
        </lastname>
        <forename>
         Yoonjung
        </forename>
        <initials>
         Y
        </initials>
        <affiliationinfo>
         <affiliation>
          Deargen, Inc., Daejeon, Republic of Korea.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Park
        </lastname>
        <forename>
         Sungsoo
        </forename>
        <initials>
         S
        </initials>
        <affiliationinfo>
         <affiliation>
          Deargen, Inc., Daejeon, Republic of Korea.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Kang
        </lastname>
        <forename>
         Keunsoo
        </forename>
        <initials>
         K
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Microbiology, College of Natural Sciences, Dankook University, Cheonan, Republic of Korea.
         </affiliation>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <publicationtypelist>
       <publicationtype ui="D016428">
        Journal Article
       </publicationtype>
      </publicationtypelist>
      <articledate datetype="Electronic">
       <year>
        2020
       </year>
       <month>
        03
       </month>
       <day>
        30
       </day>
      </articledate>
     </article>
     <medlinejournalinfo>
      <country>
       Netherlands
      </country>
      <medlineta>
       Comput Struct Biotechnol J
      </medlineta>
      <nlmuniqueid>
       101585369
      </nlmuniqueid>
      <issnlinking>
       2001-0370
      </issnlinking>
     </medlinejournalinfo>
     <keywordlist owner="NOTNLM">
      <keyword majortopicyn="N">
       Atazanavir
      </keyword>
      <keyword majortopicyn="N">
       COVID-19
      </keyword>
      <keyword majortopicyn="N">
       Coronavirus
      </keyword>
      <keyword majortopicyn="N">
       Deep learning
      </keyword>
      <keyword majortopicyn="N">
       Drug repurposing
      </keyword>
      <keyword majortopicyn="N">
       MT-DTI
      </keyword>
      <keyword majortopicyn="N">
       SARS-CoV-2
      </keyword>
     </keywordlist>
     <coistatement>
      Beck B.R., Choi Y., and Park S. are employed by company Deargen Inc. Shin B. is employed by Deargen Inc as a part-time advisor. Kang K. is one of the co-founders of, and a shareholder in, Deargen Inc.
     </coistatement>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="received">
       <year>
        2020
       </year>
       <month>
        02
       </month>
       <day>
        22
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="revised">
       <year>
        2020
       </year>
       <month>
        03
       </month>
       <day>
        23
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="accepted">
       <year>
        2020
       </year>
       <month>
        03
       </month>
       <day>
        25
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        14
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        14
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        14
       </day>
       <hour>
        6
       </hour>
       <minute>
        1
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      epublish
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32280433
      </articleid>
      <articleid idtype="doi">
       10.1016/j.csbj.2020.03.025
      </articleid>
      <articleid idtype="pii">
       S2001-0370(20)30049-0
      </articleid>
      <articleid idtype="pmc">
       PMC7118541
      </articleid>
     </articleidlist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="Publisher">
     <pmid version="1">
      32277367
     </pmid>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       11
      </day>
     </daterevised>
     <article pubmodel="Print-Electronic">
      <journal>
       <issn issntype="Electronic">
        1434-9949
       </issn>
       <journalissue citedmedium="Internet">
        <pubdate>
         <year>
          2020
         </year>
         <month>
          Apr
         </month>
         <day>
          10
         </day>
        </pubdate>
       </journalissue>
       <title>
        Clinical rheumatology
       </title>
       <isoabbreviation>
        Clin. Rheumatol.
       </isoabbreviation>
      </journal>
      <articletitle>
       Rheumatologists' perspective on coronavirus disease 19 (COVID-19) and potential therapeutic targets.
      </articletitle>
      <elocationid eidtype="doi" validyn="Y">
       10.1007/s10067-020-05073-9
      </elocationid>
      <abstract>
       <abstracttext>
        The ongoing pandemic coronavirus disease 19 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a matter of global concern. Environmental factors such as air pollution and smoking and comorbid conditions (hypertension, diabetes mellitus and underlying cardio-respiratory illness) likely increase the severity of COVID-19. Rheumatic manifestations such as arthralgias and arthritis may be prevalent in about a seventh of individuals. COVID-19 can result in acute interstitial pneumonia, myocarditis, leucopenia (with lymphopenia) and thrombocytopenia, also seen in rheumatic diseases like lupus and Sjogren's syndrome. Severe disease in a subset of patients may be driven by cytokine storm, possibly due to secondary hemophagocytic lymphohistiocytosis (HLH), akin to that in systemic onset juvenile idiopathic arthritis or adult-onset Still's disease. In the absence of high-quality evidence in this emerging disease, understanding of pathogenesis may help postulate potential therapies. Angiotensin converting enzyme 2 (ACE2) appears important for viral entry into pneumocytes; dysbalance in ACE2 as caused by ACE inhibitors or ibuprofen may predispose to severe disease. Preliminary evidence suggests potential benefit with chloroquine or hydroxychloroquine. Antiviral drugs like lopinavir/ritonavir, favipiravir and remdesivir are also being explored. Cytokine storm and secondary HLH might require heightened immunosuppressive regimens. Current international society recommendations suggest that patients with rheumatic diseases on immunosuppressive therapy should not stop glucocorticoids during COVID-19 infection, although minimum possible doses may be used. Disease-modifying drugs should be continued; cessation may be considered during infection episodes as per standard practices. Development of a vaccine may be the only effective long-term protection against this disease.Key Points• Patients with coronavirus disease 19 (COVID-19) may have features mimicking rheumatic diseases, such as arthralgias, acute interstitial pneumonia, myocarditis, leucopenia, lymphopenia, thrombocytopenia and cytokine storm with features akin to secondary hemophagocytic lymphohistiocytosis.• Although preliminary results may be encouraging, high-quality clinical trials are needed to better understand the role of drugs commonly used in rheumatology like hydroxychloroquine and tocilizumab in COVID-19.• Until further evidence emerges, it may be cautiously recommended to continue glucocorticoids and other disease-modifying antirheumatic drugs (DMARDs) in patients receiving these therapies, with discontinuation of DMARDs during infections as per standard practice.
       </abstracttext>
      </abstract>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Misra
        </lastname>
        <forename>
         Durga Prasanna
        </forename>
        <initials>
         DP
        </initials>
        <identifier source="ORCID">
         https://orcid.org/0000-0002-5035-7396
        </identifier>
        <affiliationinfo>
         <affiliation>
          Department of Clinical Immunology and Rheumatology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India. durgapmisra@gmail.com.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Agarwal
        </lastname>
        <forename>
         Vikas
        </forename>
        <initials>
         V
        </initials>
        <identifier source="ORCID">
         https://orcid.org/0000-0002-4508-1233
        </identifier>
        <affiliationinfo>
         <affiliation>
          Department of Clinical Immunology and Rheumatology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Gasparyan
        </lastname>
        <forename>
         Armen Yuri
        </forename>
        <initials>
         AY
        </initials>
        <identifier source="ORCID">
         https://orcid.org/0000-0001-8749-6018
        </identifier>
        <affiliationinfo>
         <affiliation>
          Departments of Rheumatology and Research and Development, Dudley Group NHS Foundation Trust (Teaching Trust of the University of Birmingham, UK), Russells Hall Hospital, Dudley, West Midlands, UK.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Zimba
        </lastname>
        <forename>
         Olena
        </forename>
        <initials>
         O
        </initials>
        <identifier source="ORCID">
         https://orcid.org/0000-0002-4188-8486
        </identifier>
        <affiliationinfo>
         <affiliation>
          Department of Internal Medicine #2, Danylo Halytsky Lviv National Medical University, Lviv, Ukraine.
         </affiliation>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <publicationtypelist>
       <publicationtype ui="D016428">
        Journal Article
       </publicationtype>
       <publicationtype ui="D016454">
        Review
       </publicationtype>
      </publicationtypelist>
      <articledate datetype="Electronic">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        10
       </day>
      </articledate>
     </article>
     <medlinejournalinfo>
      <country>
       Germany
      </country>
      <medlineta>
       Clin Rheumatol
      </medlineta>
      <nlmuniqueid>
       8211469
      </nlmuniqueid>
      <issnlinking>
       0770-3198
      </issnlinking>
     </medlinejournalinfo>
     <citationsubset>
      IM
     </citationsubset>
     <keywordlist owner="NOTNLM">
      <keyword majortopicyn="N">
       COVID-19
      </keyword>
      <keyword majortopicyn="N">
       Epidemiology
      </keyword>
      <keyword majortopicyn="N">
       Hydroxychloroquine
      </keyword>
      <keyword majortopicyn="N">
       Hypothesis
      </keyword>
      <keyword majortopicyn="N">
       Immunity
      </keyword>
      <keyword majortopicyn="N">
       Pathogenesis
      </keyword>
      <keyword majortopicyn="N">
       Vaccines
      </keyword>
      <keyword majortopicyn="N">
       Vitamin D
      </keyword>
     </keywordlist>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="received">
       <year>
        2020
       </year>
       <month>
        03
       </month>
       <day>
        24
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="accepted">
       <year>
        2020
       </year>
       <month>
        03
       </month>
       <day>
        31
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="revised">
       <year>
        2020
       </year>
       <month>
        03
       </month>
       <day>
        29
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        12
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        12
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        12
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      aheadofprint
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32277367
      </articleid>
      <articleid idtype="doi">
       10.1007/s10067-020-05073-9
      </articleid>
      <articleid idtype="pii">
       10.1007/s10067-020-05073-9
      </articleid>
     </articleidlist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="In-Data-Review">
     <pmid version="1">
      32277065
     </pmid>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       18
      </day>
     </daterevised>
     <article pubmodel="Print">
      <journal>
       <issn issntype="Electronic">
        1083-351X
       </issn>
       <journalissue citedmedium="Internet">
        <volume>
         295
        </volume>
        <issue>
         15
        </issue>
        <pubdate>
         <year>
          2020
         </year>
         <month>
          Apr
         </month>
         <day>
          10
         </day>
        </pubdate>
       </journalissue>
       <title>
        The Journal of biological chemistry
       </title>
       <isoabbreviation>
        J. Biol. Chem.
       </isoabbreviation>
      </journal>
      <articletitle>
       Halting coronavirus polymerase.
      </articletitle>
      <pagination>
       <medlinepgn>
        4780-4781
       </medlinepgn>
      </pagination>
      <elocationid eidtype="doi" validyn="Y">
       10.1074/jbc.H120.013397
      </elocationid>
      <abstract>
       <abstracttext>
        The nucleotide analogue remdesivir is an investigational drug for the treatment of human coronavirus infection. Remdesivir is a phosphoramidate prodrug and is known to target viral RNA-dependent RNA polymerases. In this issue, Gordon
        <i>
         et al.
        </i>
        identify that remdesivir acts as a delayed RNA chain terminator for MERS-CoV polymerase complexes.
       </abstracttext>
       <copyrightinformation>
        © 2020 Kirchdoerfer.
       </copyrightinformation>
      </abstract>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Kirchdoerfer
        </lastname>
        <forename>
         Robert N
        </forename>
        <initials>
         RN
        </initials>
        <identifier source="ORCID">
         https://orcid.org/0000-0002-5974-2709
        </identifier>
        <affiliationinfo>
         <affiliation>
          Department of Biochemistry, University of Wisconsin-Madison, Madison, Wisconsin 53706 rnkirchdoerf@wisc.edu.
         </affiliation>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <publicationtypelist>
       <publicationtype ui="D016428">
        Journal Article
       </publicationtype>
      </publicationtypelist>
     </article>
     <medlinejournalinfo>
      <country>
       United States
      </country>
      <medlineta>
       J Biol Chem
      </medlineta>
      <nlmuniqueid>
       2985121R
      </nlmuniqueid>
      <issnlinking>
       0021-9258
      </issnlinking>
     </medlinejournalinfo>
     <citationsubset>
      IM
     </citationsubset>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        12
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        12
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        12
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      ppublish
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32277065
      </articleid>
      <articleid idtype="pii">
       295/15/4780
      </articleid>
      <articleid idtype="doi">
       10.1074/jbc.H120.013397
      </articleid>
      <articleid idtype="pmc">
       PMC7152748
      </articleid>
     </articleidlist>
     <referencelist>
      <reference>
       <citation>
        Sci Transl Med. 2017 Jun 28;9(396):
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         28659436
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Sci Rep. 2017 Mar 06;7:43395
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         28262699
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Nat Commun. 2019 May 28;10(1):2342
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         31138817
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        mBio. 2018 Mar 6;9(2):
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         29511076
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Biol Chem. 2020 Apr 10;295(15):4773-4779
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32094225
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Nature. 2016 Mar 17;531(7594):381-5
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         26934220
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        PLoS Pathog. 2013 Aug;9(8):e1003565
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         23966862
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Virus Res. 2017 Apr 15;234:58-73
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         28174054
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Proc Natl Acad Sci U S A. 2014 Sep 16;111(37):E3900-9
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         25197083
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Antivir Chem Chemother. 2018 Jan-Dec;26:2040206618764483
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         29562753
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="Publisher">
     <pmid version="1">
      32277040
     </pmid>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       11
      </day>
     </daterevised>
     <article pubmodel="Print-Electronic">
      <journal>
       <issn issntype="Electronic">
        1095-9203
       </issn>
       <journalissue citedmedium="Internet">
        <pubdate>
         <year>
          2020
         </year>
         <month>
          Apr
         </month>
         <day>
          10
         </day>
        </pubdate>
       </journalissue>
       <title>
        Science (New York, N.Y.)
       </title>
       <isoabbreviation>
        Science
       </isoabbreviation>
      </journal>
      <articletitle>
       Structure of the RNA-dependent RNA polymerase from COVID-19 virus.
      </articletitle>
      <elocationid eidtype="pii" validyn="Y">
       eabb7498
      </elocationid>
      <elocationid eidtype="doi" validyn="Y">
       10.1126/science.abb7498
      </elocationid>
      <abstract>
       <abstracttext>
        A novel coronavirus (COVID-19 virus) outbreak has caused a global pandemic resulting in tens of thousands of infections and thousands of deaths worldwide. The RNA-dependent RNA polymerase (RdRp, also named nsp12) is the central component of coronaviral replication/transcription machinery and appears to be a primary target for the antiviral drug, remdesivir. We report the cryo-EM structure of COVID-19 virus full-length nsp12 in complex with cofactors nsp7 and nsp8 at 2.9-Å resolution. In addition to the conserved architecture of the polymerase core of the viral polymerase family, nsp12 possesses a newly identified β-hairpin domain at its N terminus. A comparative analysis model shows how remdesivir binds to this polymerase. The structure provides a basis for the design of new antiviral therapeutics targeting viral RdRp.
       </abstracttext>
       <copyrightinformation>
        Copyright © 2020 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.
       </copyrightinformation>
      </abstract>
      <authorlist completeyn="Y">
       <author equalcontrib="Y" validyn="Y">
        <lastname>
         Gao
        </lastname>
        <forename>
         Yan
        </forename>
        <initials>
         Y
        </initials>
        <identifier source="ORCID">
         https://orcid.org/0000-0002-0364-6427
        </identifier>
        <affiliationinfo>
         <affiliation>
          Laboratory of Structural Biology, School of Life Sciences, and School of Medicine, Tsinghua University, Beijing, China.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          Shanghai Institute for Advanced Immunochemical Studies and School of Life Science and Technology, ShanghaiTech University, Shanghai, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author equalcontrib="Y" validyn="Y">
        <lastname>
         Yan
        </lastname>
        <forename>
         Liming
        </forename>
        <initials>
         L
        </initials>
        <identifier source="ORCID">
         https://orcid.org/0000-0003-0648-9604
        </identifier>
        <affiliationinfo>
         <affiliation>
          Laboratory of Structural Biology, School of Life Sciences, and School of Medicine, Tsinghua University, Beijing, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author equalcontrib="Y" validyn="Y">
        <lastname>
         Huang
        </lastname>
        <forename>
         Yucen
        </forename>
        <initials>
         Y
        </initials>
        <affiliationinfo>
         <affiliation>
          Laboratory of Structural Biology, School of Life Sciences, and School of Medicine, Tsinghua University, Beijing, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author equalcontrib="Y" validyn="Y">
        <lastname>
         Liu
        </lastname>
        <forename>
         Fengjiang
        </forename>
        <initials>
         F
        </initials>
        <identifier source="ORCID">
         https://orcid.org/0000-0002-9400-308X
        </identifier>
        <affiliationinfo>
         <affiliation>
          Shanghai Institute for Advanced Immunochemical Studies and School of Life Science and Technology, ShanghaiTech University, Shanghai, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Zhao
        </lastname>
        <forename>
         Yao
        </forename>
        <initials>
         Y
        </initials>
        <identifier source="ORCID">
         https://orcid.org/0000-0002-2932-2164
        </identifier>
        <affiliationinfo>
         <affiliation>
          Shanghai Institute for Advanced Immunochemical Studies and School of Life Science and Technology, ShanghaiTech University, Shanghai, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Cao
        </lastname>
        <forename>
         Lin
        </forename>
        <initials>
         L
        </initials>
        <affiliationinfo>
         <affiliation>
          State Key Laboratory of Medicinal Chemical Biology, Frontiers Science Center for Cell Response, College of Life Sciences, and College of Pharmacy, Nankai University, Tianjin, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Wang
        </lastname>
        <forename>
         Tao
        </forename>
        <initials>
         T
        </initials>
        <identifier source="ORCID">
         https://orcid.org/0000-0002-8943-7916
        </identifier>
        <affiliationinfo>
         <affiliation>
          Laboratory of Structural Biology, School of Life Sciences, and School of Medicine, Tsinghua University, Beijing, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Sun
        </lastname>
        <forename>
         Qianqian
        </forename>
        <initials>
         Q
        </initials>
        <identifier source="ORCID">
         https://orcid.org/0000-0001-6362-904X
        </identifier>
        <affiliationinfo>
         <affiliation>
          Shanghai Institute for Advanced Immunochemical Studies and School of Life Science and Technology, ShanghaiTech University, Shanghai, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Ming
        </lastname>
        <forename>
         Zhenhua
        </forename>
        <initials>
         Z
        </initials>
        <affiliationinfo>
         <affiliation>
          State Key Laboratory for Conservation and Utilization of Subtropical Agro-Bioresources, College of Life Science and Technology, Guangxi University, Nanning, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Zhang
        </lastname>
        <forename>
         Lianqi
        </forename>
        <initials>
         L
        </initials>
        <affiliationinfo>
         <affiliation>
          Laboratory of Structural Biology, School of Life Sciences, and School of Medicine, Tsinghua University, Beijing, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Ge
        </lastname>
        <forename>
         Ji
        </forename>
        <initials>
         J
        </initials>
        <affiliationinfo>
         <affiliation>
          Laboratory of Structural Biology, School of Life Sciences, and School of Medicine, Tsinghua University, Beijing, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Zheng
        </lastname>
        <forename>
         Litao
        </forename>
        <initials>
         L
        </initials>
        <affiliationinfo>
         <affiliation>
          Laboratory of Structural Biology, School of Life Sciences, and School of Medicine, Tsinghua University, Beijing, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Zhang
        </lastname>
        <forename>
         Ying
        </forename>
        <initials>
         Y
        </initials>
        <affiliationinfo>
         <affiliation>
          Laboratory of Structural Biology, School of Life Sciences, and School of Medicine, Tsinghua University, Beijing, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Wang
        </lastname>
        <forename>
         Haofeng
        </forename>
        <initials>
         H
        </initials>
        <identifier source="ORCID">
         https://orcid.org/0000-0001-8175-5621
        </identifier>
        <affiliationinfo>
         <affiliation>
          Shanghai Institute for Advanced Immunochemical Studies and School of Life Science and Technology, ShanghaiTech University, Shanghai, China.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          School of Life Sciences, Tianjin University, Tianjin, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Zhu
        </lastname>
        <forename>
         Yan
        </forename>
        <initials>
         Y
        </initials>
        <affiliationinfo>
         <affiliation>
          Shanghai Institute for Advanced Immunochemical Studies and School of Life Science and Technology, ShanghaiTech University, Shanghai, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Zhu
        </lastname>
        <forename>
         Chen
        </forename>
        <initials>
         C
        </initials>
        <affiliationinfo>
         <affiliation>
          Shanghai Institute for Advanced Immunochemical Studies and School of Life Science and Technology, ShanghaiTech University, Shanghai, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Hu
        </lastname>
        <forename>
         Tianyu
        </forename>
        <initials>
         T
        </initials>
        <identifier source="ORCID">
         https://orcid.org/0000-0003-2002-4280
        </identifier>
        <affiliationinfo>
         <affiliation>
          Shanghai Institute for Advanced Immunochemical Studies and School of Life Science and Technology, ShanghaiTech University, Shanghai, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Hua
        </lastname>
        <forename>
         Tian
        </forename>
        <initials>
         T
        </initials>
        <affiliationinfo>
         <affiliation>
          Shanghai Institute for Advanced Immunochemical Studies and School of Life Science and Technology, ShanghaiTech University, Shanghai, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Zhang
        </lastname>
        <forename>
         Bing
        </forename>
        <initials>
         B
        </initials>
        <identifier source="ORCID">
         https://orcid.org/0000-0001-8556-8049
        </identifier>
        <affiliationinfo>
         <affiliation>
          Shanghai Institute for Advanced Immunochemical Studies and School of Life Science and Technology, ShanghaiTech University, Shanghai, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Yang
        </lastname>
        <forename>
         Xiuna
        </forename>
        <initials>
         X
        </initials>
        <affiliationinfo>
         <affiliation>
          Shanghai Institute for Advanced Immunochemical Studies and School of Life Science and Technology, ShanghaiTech University, Shanghai, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Li
        </lastname>
        <forename>
         Jun
        </forename>
        <initials>
         J
        </initials>
        <identifier source="ORCID">
         https://orcid.org/0000-0003-3165-3699
        </identifier>
        <affiliationinfo>
         <affiliation>
          Shanghai Institute for Advanced Immunochemical Studies and School of Life Science and Technology, ShanghaiTech University, Shanghai, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Yang
        </lastname>
        <forename>
         Haitao
        </forename>
        <initials>
         H
        </initials>
        <identifier source="ORCID">
         https://orcid.org/0000-0002-1875-3268
        </identifier>
        <affiliationinfo>
         <affiliation>
          Shanghai Institute for Advanced Immunochemical Studies and School of Life Science and Technology, ShanghaiTech University, Shanghai, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Liu
        </lastname>
        <forename>
         Zhijie
        </forename>
        <initials>
         Z
        </initials>
        <affiliationinfo>
         <affiliation>
          Shanghai Institute for Advanced Immunochemical Studies and School of Life Science and Technology, ShanghaiTech University, Shanghai, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Xu
        </lastname>
        <forename>
         Wenqing
        </forename>
        <initials>
         W
        </initials>
        <affiliationinfo>
         <affiliation>
          Shanghai Institute for Advanced Immunochemical Studies and School of Life Science and Technology, ShanghaiTech University, Shanghai, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Guddat
        </lastname>
        <forename>
         Luke W
        </forename>
        <initials>
         LW
        </initials>
        <identifier source="ORCID">
         https://orcid.org/0000-0002-8204-8408
        </identifier>
        <affiliationinfo>
         <affiliation>
          School of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, QLD, Australia.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Wang
        </lastname>
        <forename>
         Quan
        </forename>
        <initials>
         Q
        </initials>
        <identifier source="ORCID">
         https://orcid.org/0000-0001-5148-5210
        </identifier>
        <affiliationinfo>
         <affiliation>
          Shanghai Institute for Advanced Immunochemical Studies and School of Life Science and Technology, ShanghaiTech University, Shanghai, China. wangq@shanghaitech.edu.cn louzy@mail.tsinghua.edu.cn raozh@mail.tsinghua.edu.cn.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Lou
        </lastname>
        <forename>
         Zhiyong
        </forename>
        <initials>
         Z
        </initials>
        <identifier source="ORCID">
         https://orcid.org/0000-0003-2728-881X
        </identifier>
        <affiliationinfo>
         <affiliation>
          Laboratory of Structural Biology, School of Life Sciences, and School of Medicine, Tsinghua University, Beijing, China. wangq@shanghaitech.edu.cn louzy@mail.tsinghua.edu.cn raozh@mail.tsinghua.edu.cn.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Rao
        </lastname>
        <forename>
         Zihe
        </forename>
        <initials>
         Z
        </initials>
        <identifier source="ORCID">
         https://orcid.org/0000-0001-9866-2384
        </identifier>
        <affiliationinfo>
         <affiliation>
          Laboratory of Structural Biology, School of Life Sciences, and School of Medicine, Tsinghua University, Beijing, China. wangq@shanghaitech.edu.cn louzy@mail.tsinghua.edu.cn raozh@mail.tsinghua.edu.cn.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          Shanghai Institute for Advanced Immunochemical Studies and School of Life Science and Technology, ShanghaiTech University, Shanghai, China.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          State Key Laboratory of Medicinal Chemical Biology, Frontiers Science Center for Cell Response, College of Life Sciences, and College of Pharmacy, Nankai University, Tianjin, China.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          National Laboratory of Biomacromolecules, CAS Center for Excellence in Biomacromolecules, Institute of Biophysics, CAS, Beijing, China.
         </affiliation>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <publicationtypelist>
       <publicationtype ui="D016428">
        Journal Article
       </publicationtype>
      </publicationtypelist>
      <articledate datetype="Electronic">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        10
       </day>
      </articledate>
     </article>
     <medlinejournalinfo>
      <country>
       United States
      </country>
      <medlineta>
       Science
      </medlineta>
      <nlmuniqueid>
       0404511
      </nlmuniqueid>
      <issnlinking>
       0036-8075
      </issnlinking>
     </medlinejournalinfo>
     <citationsubset>
      IM
     </citationsubset>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="received">
       <year>
        2020
       </year>
       <month>
        03
       </month>
       <day>
        16
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="accepted">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        07
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        12
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        12
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        12
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      aheadofprint
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32277040
      </articleid>
      <articleid idtype="pii">
       science.abb7498
      </articleid>
      <articleid idtype="doi">
       10.1126/science.abb7498
      </articleid>
     </articleidlist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="MEDLINE">
     <pmid version="1">
      32275256
     </pmid>
     <datecompleted>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       15
      </day>
     </datecompleted>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       15
      </day>
     </daterevised>
     <article pubmodel="Print">
      <journal>
       <issn issntype="Print">
        1124-9390
       </issn>
       <journalissue citedmedium="Internet">
        <volume>
         28
        </volume>
        <issue>
         2
        </issue>
        <pubdate>
         <medlinedate>
          2020 Ahead of print Jun 1
         </medlinedate>
        </pubdate>
       </journalissue>
       <title>
        Le infezioni in medicina
       </title>
       <isoabbreviation>
        Infez Med
       </isoabbreviation>
      </journal>
      <articletitle>
       Vademecum for the treatment of people with COVID-19. Edition 2.0, 13 March 2020.
      </articletitle>
      <pagination>
       <medlinepgn>
        143-152
       </medlinepgn>
      </pagination>
      <abstract>
       <abstracttext>
        The spread of COVID-19 epidemic in Italy, and particularly in Lombardy determined the need to standardize the therapeutic approach in order to offer the same indications for all hospitals in Lombardy. However, no specific drug has been previously approved for the COVID-19 treatment. The Lombardy Section of the Italian Society of Infectious and Tropical Diseases provided this «vademecum» with the aim to explore the current evidence about the drugs likely to be efficacious in the treatment of COVID-19. Moreover, a multidisciplinary group including critical care specialists has been created in order to provide indications about supporting measures and the use of steroids. A new grading scale has been proposed to help patients' stratification according to the severity of the respiratory conditions. Lastly, a collaborating group with immunologists and rheumatologists has been built with the aim of providing some guidance about the use of tocilizumab, a promising option for the treatment of the hyperinflammatory state occurring in most patients affected by COVID-19.
       </abstracttext>
      </abstract>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Lombardy Section Italian Society Infectious And Tropical Diseases
        </lastname>
        <forename>
         -
        </forename>
        <initials>
         -
        </initials>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <publicationtypelist>
       <publicationtype ui="D016428">
        Journal Article
       </publicationtype>
       <publicationtype ui="D017065">
        Practice Guideline
       </publicationtype>
       <publicationtype ui="D016454">
        Review
       </publicationtype>
      </publicationtypelist>
     </article>
     <medlinejournalinfo>
      <country>
       Italy
      </country>
      <medlineta>
       Infez Med
      </medlineta>
      <nlmuniqueid>
       9613961
      </nlmuniqueid>
      <issnlinking>
       1124-9390
      </issnlinking>
     </medlinejournalinfo>
     <chemicallist>
      <chemical>
       <registrynumber>
        0
       </registrynumber>
       <nameofsubstance ui="D061067">
        Antibodies, Monoclonal, Humanized
       </nameofsubstance>
      </chemical>
      <chemical>
       <registrynumber>
        0
       </registrynumber>
       <nameofsubstance ui="D000998">
        Antiviral Agents
       </nameofsubstance>
      </chemical>
      <chemical>
       <registrynumber>
        3QKI37EEHE
       </registrynumber>
       <nameofsubstance ui="C000606551">
        remdesivir
       </nameofsubstance>
      </chemical>
      <chemical>
       <registrynumber>
        415SHH325A
       </registrynumber>
       <nameofsubstance ui="D000249">
        Adenosine Monophosphate
       </nameofsubstance>
      </chemical>
      <chemical>
       <registrynumber>
        I031V2H011
       </registrynumber>
       <nameofsubstance ui="C502936">
        tocilizumab
       </nameofsubstance>
      </chemical>
      <chemical>
       <registrynumber>
        OF5P57N2ZX
       </registrynumber>
       <nameofsubstance ui="D000409">
        Alanine
       </nameofsubstance>
      </chemical>
     </chemicallist>
     <supplmeshlist>
      <supplmeshname type="Disease" ui="C000657245">
       COVID-19
      </supplmeshname>
      <supplmeshname type="Organism" ui="C000656484">
       severe acute respiratory syndrome coronavirus 2
      </supplmeshname>
     </supplmeshlist>
     <citationsubset>
      IM
     </citationsubset>
     <meshheadinglist>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D000249">
        Adenosine Monophosphate
       </descriptorname>
       <qualifiername majortopicyn="N" ui="Q000031">
        analogs &amp; derivatives
       </qualifiername>
       <qualifiername majortopicyn="N" ui="Q000627">
        therapeutic use
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D000409">
        Alanine
       </descriptorname>
       <qualifiername majortopicyn="N" ui="Q000031">
        analogs &amp; derivatives
       </qualifiername>
       <qualifiername majortopicyn="N" ui="Q000627">
        therapeutic use
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D061067">
        Antibodies, Monoclonal, Humanized
       </descriptorname>
       <qualifiername majortopicyn="N" ui="Q000627">
        therapeutic use
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D000998">
        Antiviral Agents
       </descriptorname>
       <qualifiername majortopicyn="Y" ui="Q000627">
        therapeutic use
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D000073640">
        Betacoronavirus
       </descriptorname>
       <qualifiername majortopicyn="Y" ui="Q000302">
        isolation &amp; purification
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D002985">
        Clinical Protocols
       </descriptorname>
       <qualifiername majortopicyn="N" ui="Q000592">
        standards
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D018352">
        Coronavirus Infections
       </descriptorname>
       <qualifiername majortopicyn="Y" ui="Q000188">
        drug therapy
       </qualifiername>
       <qualifiername majortopicyn="N" ui="Q000453">
        epidemiology
       </qualifiername>
       <qualifiername majortopicyn="N" ui="Q000628">
        therapy
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D006801">
        Humans
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" type="Geographic" ui="D007558">
        Italy
       </descriptorname>
       <qualifiername majortopicyn="N" ui="Q000453">
        epidemiology
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="Y" ui="D058873">
        Pandemics
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D010348">
        Patient Care Team
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D018579">
        Patient Selection
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D011024">
        Pneumonia, Viral
       </descriptorname>
       <qualifiername majortopicyn="Y" ui="Q000188">
        drug therapy
       </qualifiername>
       <qualifiername majortopicyn="N" ui="Q000453">
        epidemiology
       </qualifiername>
       <qualifiername majortopicyn="N" ui="Q000628">
        therapy
       </qualifiername>
      </meshheading>
     </meshheadinglist>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        11
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        11
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        16
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      ppublish
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32275256
      </articleid>
     </articleidlist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="PubMed-not-MEDLINE">
     <pmid version="1">
      32269893
     </pmid>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       11
      </day>
     </daterevised>
     <article pubmodel="Electronic">
      <journal>
       <issn issntype="Print">
        2168-8184
       </issn>
       <journalissue citedmedium="Print">
        <volume>
         12
        </volume>
        <issue>
         4
        </issue>
        <pubdate>
         <year>
          2020
         </year>
         <month>
          Apr
         </month>
         <day>
          06
         </day>
        </pubdate>
       </journalissue>
       <title>
        Cureus
       </title>
       <isoabbreviation>
        Cureus
       </isoabbreviation>
      </journal>
      <articletitle>
       A Comprehensive Literature Review on the Clinical Presentation, and Management of the Pandemic Coronavirus Disease 2019 (COVID-19).
      </articletitle>
      <pagination>
       <medlinepgn>
        e7560
       </medlinepgn>
      </pagination>
      <elocationid eidtype="doi" validyn="Y">
       10.7759/cureus.7560
      </elocationid>
      <abstract>
       <abstracttext>
        Coronavirus disease 2019 (COVID-19) is a declared global pandemic. There are multiple parameters of the clinical course and management of the COVID-19 that need optimization. A hindrance to this development is the vast amount of misinformation present due to scarcely sourced manuscript preprints and social media. This literature review aims to presents accredited and the most current studies pertaining to the basic sciences of SARS-CoV-2, clinical presentation and disease course of COVID-19, public health interventions, and current epidemiological developments. The review on basic sciences aims to clarify the jargon in virology, describe the virion structure of SARS-CoV-2 and present pertinent details relevant to clinical practice. Another component discussed is the brief history on the series of experiments used to explore the origins and evolution of the phylogeny of the viral genome of SARS-CoV-2. Additionally, the clinical and epidemiological differences between COVID-19 and other infections causing outbreaks (SARS, MERS, H1N1) are elucidated. Emphasis is placed on evidence-based medicine to evaluate the frequency of presentation of various symptoms to create a stratification system of the most important epidemiological risk factors for COVID-19. These can be used to triage and expedite risk assessment. Furthermore, the limitations and statistical strength of the diagnostic tools currently in clinical practice are evaluated. Criteria on rapid screening, discharge from hospital and discontinuation of self-quarantine are clarified. Epidemiological factors influencing the rapid rate of spread of the SARS-CoV-2 virus are described. Accurate information pertinent to improving prevention strategies is also discussed. The penultimate portion of the review aims to explain the involvement of micronutrients such as vitamin C and vitamin D in COVID19 treatment and prophylaxis. Furthermore, the biochemistry of the major candidates for novel therapies is briefly reviewed and a summary of their current status in the clinical trials is presented. Lastly, the current scientific data and status of governing bodies such as the Center of Disease Control (CDC) and the WHO on the usage of controversial therapies such as angiotensin-converting enzyme (ACE) inhibitors, nonsteroidal anti-inflammatory drugs (NSAIDs) (Ibuprofen), and corticosteroids usage in COVID-19 are discussed. The composite collection of accredited studies on each of these subtopics of COVID-19 within this review will enable clarification and focus on the current status and direction in the planning of the management of this global pandemic.
       </abstracttext>
       <copyrightinformation>
        Copyright © 2020, Kakodkar et al.
       </copyrightinformation>
      </abstract>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Kakodkar
        </lastname>
        <forename>
         Pramath
        </forename>
        <initials>
         P
        </initials>
        <affiliationinfo>
         <affiliation>
          Medicine, National University of Ireland Galway, Galway, IRL.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Kaka
        </lastname>
        <forename>
         Nagham
        </forename>
        <initials>
         N
        </initials>
        <affiliationinfo>
         <affiliation>
          Medicine, National University of Ireland Galway, Galway, IRL.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Baig
        </lastname>
        <forename>
         M N
        </forename>
        <initials>
         MN
        </initials>
        <affiliationinfo>
         <affiliation>
          Orthopaedics, University Hospital Galway, Galway, IRL.
         </affiliation>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <publicationtypelist>
       <publicationtype ui="D016428">
        Journal Article
       </publicationtype>
       <publicationtype ui="D016454">
        Review
       </publicationtype>
      </publicationtypelist>
      <articledate datetype="Electronic">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        06
       </day>
      </articledate>
     </article>
     <medlinejournalinfo>
      <country>
       United States
      </country>
      <medlineta>
       Cureus
      </medlineta>
      <nlmuniqueid>
       101596737
      </nlmuniqueid>
      <issnlinking>
       2168-8184
      </issnlinking>
     </medlinejournalinfo>
     <keywordlist owner="NOTNLM">
      <keyword majortopicyn="N">
       ace2
      </keyword>
      <keyword majortopicyn="N">
       ards
      </keyword>
      <keyword majortopicyn="N">
       chloroquine
      </keyword>
      <keyword majortopicyn="N">
       covid-19
      </keyword>
      <keyword majortopicyn="N">
       lopinavir and ritonavir
      </keyword>
      <keyword majortopicyn="N">
       mrna-1273 vaccine
      </keyword>
      <keyword majortopicyn="N">
       pandemic
      </keyword>
      <keyword majortopicyn="N">
       remdesivir (gs-5734)
      </keyword>
      <keyword majortopicyn="N">
       sars-cov-2
      </keyword>
      <keyword majortopicyn="N">
       severe acute respiratory infection
      </keyword>
     </keywordlist>
     <coistatement>
      The authors have declared that no competing interests exist.
     </coistatement>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        10
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        10
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        10
       </day>
       <hour>
        6
       </hour>
       <minute>
        1
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      epublish
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32269893
      </articleid>
      <articleid idtype="doi">
       10.7759/cureus.7560
      </articleid>
      <articleid idtype="pmc">
       PMC7138423
      </articleid>
     </articleidlist>
     <referencelist>
      <reference>
       <citation>
        Euro Surveill. 2015 Jun 25;20(25):14-8
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         26132768
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Drug Discov Ther. 2020;14(1):58-60
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32147628
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        JAMA. 2020 Mar 4;:
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32129805
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Cell Res. 2020 Mar;30(3):269-271
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32020029
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Am J Epidemiol. 2004 Sep 15;160(6):509-16
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         15353409
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Lancet. 2020 Mar 28;395(10229):1054-1062
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32171076
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Med Virol. 2020 Apr;92(4):401-402
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         31950516
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Nutrients. 2020 Jan 22;12(2):
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         31978969
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Curr Biol. 2020 Apr 6;30(7):1346-1351.e2
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32197085
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Anesthesiology. 2019 Apr;130(4):581-591
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         30676417
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Lancet. 2020 Feb 15;395(10223):497-506
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         31986264
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        BMJ. 2017 Feb 15;356:i6583
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         28202713
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Science. 2005 Oct 28;310(5748):676-9
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         16195424
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        BMC Med. 2009 Jun 22;7:30
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         19545404
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Nature. 2020 Mar;579(7798):270-273
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32015507
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        N Engl J Med. 2020 Mar 26;382(13):1199-1207
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         31995857
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Radiology. 2020 Feb 26;:200642
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32101510
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Thorax. 2004 Mar;59(3):252-6
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         14985565
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Lancet. 2020 Mar 7;395(10226):809-815
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32151335
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Hypertension. 2004 May;43(5):970-6
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         15007027
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Am J Hypertens. 2015 Jan;28(1):15-21
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         24842388
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Lancet Infect Dis. 2020 Apr;20(4):425-434
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32105637
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Viruses. 2019 Oct 24;11(11):
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         31652964
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        N Engl J Med. 2020 Mar 17;:
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32182409
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Hosp Infect. 2020 Mar;104(3):246-251
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32035997
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Clin Infect Dis. 2020 Mar 09;:
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32150618
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Crit Care Med. 2017 Oct;45(10):1683-1695
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         28787295
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Lancet Infect Dis. 2005 Nov;5(11):718-25
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         16253889
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        N Engl J Med. 2020 Mar 18;:
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32187464
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Sci China Life Sci. 2020 Mar;63(3):457-460
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32009228
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Cell Mol Med. 2015 Aug;19(8):1965-74
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         25766467
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        PLoS One. 2018 Nov 5;13(11):e0205535
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         30395570
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Lancet Respir Med. 2020 Apr;8(4):e21
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32171062
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        PLoS Pathog. 2018 Aug 13;14(8):e1007236
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         30102747
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Hosp Infect. 2016 Mar;92(3):235-50
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         26597631
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Lancet. 2020 Feb 15;395(10223):507-513
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32007143
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="PubMed-not-MEDLINE">
     <pmid version="1">
      32258351
     </pmid>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       17
      </day>
     </daterevised>
     <article pubmodel="Electronic-eCollection">
      <journal>
       <issn issntype="Print">
        2352-7714
       </issn>
       <journalissue citedmedium="Print">
        <volume>
         9
        </volume>
        <pubdate>
         <year>
          2020
         </year>
         <month>
          Jun
         </month>
        </pubdate>
       </journalissue>
       <title>
        One health (Amsterdam, Netherlands)
       </title>
       <isoabbreviation>
        One Health
       </isoabbreviation>
      </journal>
      <articletitle>
       Current knowledge about the antivirals remdesivir (GS-5734) and GS-441524 as therapeutic options for coronaviruses.
      </articletitle>
      <pagination>
       <medlinepgn>
        100128
       </medlinepgn>
      </pagination>
      <elocationid eidtype="doi" validyn="Y">
       10.1016/j.onehlt.2020.100128
      </elocationid>
      <abstract>
       <abstracttext>
        Recent international epidemics of coronavirus-associated illnesses underscore the urgent medical and public health need for vaccine development and regulatory body approved therapies. In particular, the current coronavirus disease 2019 (COVID-19) pandemic has quickly intensified interest in developing treatment options to mitigate impact on human life. Remdesivir (GS-5734™) is a broad-spectrum antiviral drug that is now being tested as a potential treatment for COVID-19 in international, multi-site clinical trials. Currently available evidence about the antiviral effects of remdesivir against coronaviruses is primarily based on
        <i>
         in vitro
        </i>
        and
        <i>
         in vivo
        </i>
        studies (including some on a chemically related compound, GS-441524™), which have demonstrated largely favorable findings. As the pandemic progresses, information from human compassionate use cases will continue to accumulate before the clinical trials are concluded. It is imperative for public health practitioners and the One Health community to stay up to date on the most promising potential therapeutic options that are under investigation. Thus, the purpose of this review is to synthesize the knowledge to date about remdesivir as a therapeutic option for coronaviruses, with a special focus on information relevant to the One Health community.
       </abstracttext>
       <copyrightinformation>
        © 2020 The Authors. Published by Elsevier B.V.
       </copyrightinformation>
      </abstract>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Amirian
        </lastname>
        <forename>
         E Susan
        </forename>
        <initials>
         ES
        </initials>
        <affiliationinfo>
         <affiliation>
          Public Health &amp; Healthcare Program, Texas Policy Lab, School of Social Sciences, Rice University, Houston, TX, USA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Levy
        </lastname>
        <forename>
         Julie K
        </forename>
        <initials>
         JK
        </initials>
        <affiliationinfo>
         <affiliation>
          Maddie's Shelter Medicine Program, College of Veterinary Medicine, University of Florida, Gainesville, FL, USA.
         </affiliation>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <publicationtypelist>
       <publicationtype ui="D016428">
        Journal Article
       </publicationtype>
       <publicationtype ui="D016454">
        Review
       </publicationtype>
      </publicationtypelist>
      <articledate datetype="Electronic">
       <year>
        2020
       </year>
       <month>
        03
       </month>
       <day>
        27
       </day>
      </articledate>
     </article>
     <medlinejournalinfo>
      <country>
       Netherlands
      </country>
      <medlineta>
       One Health
      </medlineta>
      <nlmuniqueid>
       101660501
      </nlmuniqueid>
      <issnlinking>
       2352-7714
      </issnlinking>
     </medlinejournalinfo>
     <keywordlist owner="NOTNLM">
      <keyword majortopicyn="N">
       COVID-19
      </keyword>
      <keyword majortopicyn="N">
       Compassionate use
      </keyword>
      <keyword majortopicyn="N">
       Coronavirus
      </keyword>
      <keyword majortopicyn="N">
       GS-5734
      </keyword>
      <keyword majortopicyn="N">
       Remdesivir
      </keyword>
      <keyword majortopicyn="N">
       SARS-CoV-2
      </keyword>
     </keywordlist>
     <coistatement>
      The authors report no relevant conflicts of interest. E.S. Amirian was previously employed by McKesson Specialty Health, where she conducted health economics and outcomes research contract studies. However, none of these studies involved Gilead Sciences.
     </coistatement>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="received">
       <year>
        2020
       </year>
       <month>
        03
       </month>
       <day>
        15
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="revised">
       <year>
        2020
       </year>
       <month>
        03
       </month>
       <day>
        24
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="accepted">
       <year>
        2020
       </year>
       <month>
        03
       </month>
       <day>
        24
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        8
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        8
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        8
       </day>
       <hour>
        6
       </hour>
       <minute>
        1
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      epublish
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32258351
      </articleid>
      <articleid idtype="doi">
       10.1016/j.onehlt.2020.100128
      </articleid>
      <articleid idtype="pii">
       S2352-7714(20)30038-0
      </articleid>
      <articleid idtype="pii">
       100128
      </articleid>
      <articleid idtype="pmc">
       PMC7118644
      </articleid>
     </articleidlist>
     <referencelist>
      <reference>
       <citation>
        Lancet. 2020 Feb 22;395(10224):565-574
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32007145
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Case Rep Infect Dis. 2018 Apr 15;2018:6796839
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         29850307
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Sci Transl Med. 2017 Jun 28;9(396):
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         28659436
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Lancet Infect Dis. 2015 May;15(5):559-64
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         25863564
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Antiviral Res. 2019 Sep;169:104541
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         31233808
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Bioessays. 2017 Dec;39(12):
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         29052843
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Nat Commun. 2019 May 28;10(1):2342
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         31138817
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Curr Opin Virol. 2011 Dec;1(6):624-34
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         22180768
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Pathogens. 2020 Feb 22;9(2):
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32098302
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Nat Rev Microbiol. 2016 Aug;14(8):523-34
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         27344959
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        JAMA. 2020 Jan 23;:
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         31971553
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Med Virol. 2020 Feb 28;:
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32108352
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Feline Med Surg. 2019 Apr;21(4):271-281
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         30755068
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Virol. 2010 Apr;84(7):3134-46
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         19906932
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Vet Microbiol. 2018 Jun;219:226-233
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         29778200
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Emerg Infect Dis. 2017 Sep;23(9):
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         28654418
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Cell Discov. 2020 Feb 24;6:11
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32133153
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Vet Microbiol. 2015 Feb 25;175(2-4):157-66
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         25532961
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Cell Res. 2020 Mar;30(3):269-271
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32020029
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Sci Rep. 2017 Mar 06;7:43395
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         28262699
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Clin Infect Dis. 2000 Jul;31(1):96-100
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         10913403
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Virus Res. 2015 Apr 16;202:120-34
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         25445340
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Gen Virol. 2006 Nov;87(Pt 11):3349-53
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         17030869
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        N Engl J Med. 2020 Mar 5;382(10):929-936
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32004427
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Viruses. 2019 Apr 04;11(4):
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         30987343
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        mBio. 2018 Mar 6;9(2):
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         29511076
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Proc Natl Acad Sci U S A. 2020 Mar 24;117(12):6771-6776
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32054787
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        N Engl J Med. 2019 Dec 12;381(24):2293-2303
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         31774950
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Antiviral Res. 2018 Dec;160:79-86
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         30342822
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Biol Chem. 2020 Apr 10;295(15):4773-4779
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32094225
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Nature. 2016 Mar 17;531(7594):381-5
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         26934220
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Chembiochem. 2020 Mar 2;21(5):730-738
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32022370
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Nat Commun. 2020 Jan 10;11(1):222
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         31924756
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        PLoS Biol. 2005 Oct;3(10):e324
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         16128623
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Exp Biol Med (Maywood). 2009 Oct;234(10):1117-27
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         19546349
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Bioorg Med Chem Lett. 2012 Apr 15;22(8):2705-7
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         22446091
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        One Health. 2020 Feb 14;9:100123
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32140538
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        One Health. 2020 Feb 24;9:100124
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32195311
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="PubMed-not-MEDLINE">
     <pmid version="1">
      32256547
     </pmid>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       09
      </day>
     </daterevised>
     <article pubmodel="Electronic-eCollection">
      <journal>
       <issn issntype="Electronic">
        1680-5348
       </issn>
       <journalissue citedmedium="Internet">
        <volume>
         44
        </volume>
        <pubdate>
         <year>
          2020
         </year>
        </pubdate>
       </journalissue>
       <title>
        Revista panamericana de salud publica = Pan American journal of public health
       </title>
       <isoabbreviation>
        Rev. Panam. Salud Publica
       </isoabbreviation>
      </journal>
      <articletitle>
       Clinical trials on drug repositioning for COVID-19 treatment.
      </articletitle>
      <pagination>
       <medlinepgn>
        e40
       </medlinepgn>
      </pagination>
      <elocationid eidtype="doi" validyn="Y">
       10.26633/RPSP.2020.40
      </elocationid>
      <abstract>
       <abstracttext>
        The World Health Organization (WHO) was informed on December 2019 about a coronavirus pneumonia outbreak in Wuhan, Hubei province (China). Subsequently, on March 12, 2020, 125,048 cases and 4,614 deaths were reported. Coronavirus is an enveloped RNA virus, from the genus
        <i>
         Betacoronavirus
        </i>
        , that is distributed in birds, humans, and other mammals. WHO has named the novel coronavirus disease as COVID-19. More than 80 clinical trials have been launched to test coronavirus treatment, including some drug repurposing or repositioning for COVID-19. Hence, we performed a search in March 2020 of the clinicaltrials.gov database. The eligibility criteria for the retrieved studies were: contain a clinicaltrials.gov base identifier number; describe the number of participants and the period for the study; describe the participants' clinical conditions; and utilize interventions with medicines already studied or approved for any other disease in patients infected with the novel coronavirus SARS-CoV-2 (2019-nCoV). It is essential to emphasize that this article only captured trials listed in the clinicaltrials.gov database. We identified 24 clinical trials, involving more than 20 medicines, such as human immunoglobulin, interferons, chloroquine, hydroxychloroquine, arbidol, remdesivir, favipiravir, lopinavir, ritonavir, oseltamivir, methylprednisolone, bevacizumab, and traditional Chinese medicines (TCM). Although drug repurposing has some limitations, repositioning clinical trials may represent an attractive strategy because they facilitate the discovery of new classes of medicines; they have lower costs and take less time to reach the market; and there are existing pharmaceutical supply chains for formulation and distribution.
       </abstracttext>
      </abstract>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Rosa
        </lastname>
        <forename>
         Sandro G Viveiros
        </forename>
        <initials>
         SGV
        </initials>
        <affiliationinfo>
         <affiliation>
          Universidade Federal Fluminense Universidade Federal Fluminense Brazil Universidade Federal Fluminense, Rio de Janeiro, Brazil.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Santos
        </lastname>
        <forename>
         Wilson C
        </forename>
        <initials>
         WC
        </initials>
        <affiliationinfo>
         <affiliation>
          Universidade Federal Fluminense Universidade Federal Fluminense Brazil Universidade Federal Fluminense, Rio de Janeiro, Brazil.
         </affiliation>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <publicationtypelist>
       <publicationtype ui="D016428">
        Journal Article
       </publicationtype>
      </publicationtypelist>
      <articledate datetype="Electronic">
       <year>
        2020
       </year>
       <month>
        03
       </month>
       <day>
        20
       </day>
      </articledate>
     </article>
     <medlinejournalinfo>
      <country>
       United States
      </country>
      <medlineta>
       Rev Panam Salud Publica
      </medlineta>
      <nlmuniqueid>
       9705400
      </nlmuniqueid>
      <issnlinking>
       1020-4989
      </issnlinking>
     </medlinejournalinfo>
     <otherabstract language="spa" type="Publisher">
      <abstracttext>
       En diciembre de 2019 fue informado a la Organización Mundial de la Salud (OMS) un brote de neumonía por coronavirus en Wuhan, provincia de Hubei, China. Al 12 de marzo de 2020, se habían notificado 125 048 casos y 4 614 muertes. El coronavirus es un virus ARN envuelto del género
       <i>
        Betacoronavirus
       </i>
       distribuido en aves, seres humanos y otros mamíferos. La OMS ha denominado a la nueva enfermedad por coronavirus COVID-19. Se han puesto en marcha más de 80 ensayos clínicos para evaluar un tratamiento para el coronavirus, que incluyen algunos ensayos de reposicionamiento de medicamentos para la COVID-19. En marzo de 2020 se llevó a cabo una búsqueda de los ensayos clínicos registrados en la base de datos clinicaltrials.gov. Los criterios de elegibilidad para los estudios recuperados fueron tener un número de identificación de la base de datos clinicaltrials.gov; describir el número de participantes y el período del estudio; describir las condiciones clínicas de los participantes; y emplear intervenciones con medicamentos ya estudiados o aprobados para cualquier otra enfermedad en pacientes infectados con el nuevo coronavirus SARS-CoV-2 (2019-nCoV). Es esencial destacar que este artículo solo recoge los ensayos que figuran en la base de datos clinicaltrials. gov. Se identificaron 24 ensayos clínicos relacionados con más de 20 medicamentos, como inmunoglobulina humana, interferones, cloroquina, hidroxicloroquina, arbidol, remdesivir, favipiravir, lopinavir, ritonavir, oseltamivir, metilprednisolona, bevacizumab y medicina tradicional china. Aunque el reposicionamiento de medicamentos tiene algunas limitaciones, el reposicionamiento de los ensayos clínicos puede representar una estrategia atractiva porque facilita el descubrimiento de nuevas clases de medicamentos; estos tienen costos más bajos y tardan menos en llegar al mercado; y existen cadenas de suministro farmacéutico que apoyan la formulación y la distribución.
      </abstracttext>
     </otherabstract>
     <otherabstract language="por" type="Publisher">
      <abstracttext>
       A Organização Mundial da Saúde (OMS) foi informada, em dezembro de 2019, sobre um surto de pneumonia por coronavírus em Wuhan, província de Hubei (China). Posteriormente, em 12 de março de 2020, 125 048 casos e 4 614 mortes haviam sido registrados. O coronavírus é um vírus RNA envelopado do gênero
       <i>
        Betacoronavírus,
       </i>
       distribuído em aves e em humanos e outros mamíferos. A OMS designou a nova doença por coronavírus como COVID-19. Mais de 80 ensaios clínicos foram iniciados para testar tratamentos para o coronavírus, incluindo alguns de reposicionamento de medicamentos para o COVID-19. Assim, em março de 2020 realizou-se uma busca na base de dados clinicaltrials.gov. Os critérios de elegibilidade para os estudos recuperados foram: conter o número identificador da base de dados clinicaltrials.gov; descrever o número de participantes e o período do estudo; descrever as condições clínicas dos participantes; e utilizar intervenções para tratamento de doentes infectados com o novo coronavírus SARS-CoV-2 (2019-nCoV) com medicamentos já estudados ou aprovados para qualquer outra doença. É essencial salientar que este artigo apenas capturou ensaios listados na base de dados clinicaltrials.gov. Foram identificados 24 ensaios clínicos envolvendo mais de 20 medicamentos, tais como imunoglobulina humana, interferons, cloroquina, hidroxicloroquina, arbidol, remdesivir, favipiravir, lopinavir, ritonavir, oseltamivir, metilprednisolona, bevacizumabe e medicamentos chineses tradicionais. Embora o reposicionamento de medicamentos tenha algumas limitações, os ensaios clínicos de reposicionamento podem representar uma estratégia atraente, porque facilitam a descoberta de novas classes de medicamentos, têm custos mais baixos, levam menos tempo para chegar ao mercado e se beneficiam de cadeias de fornecimento farmacêutico já existentes para formulação e distribuição.
      </abstracttext>
     </otherabstract>
     <keywordlist owner="NOTNLM">
      <keyword majortopicyn="N">
       Drug repositioning
      </keyword>
      <keyword majortopicyn="N">
       clinical trials as topic
      </keyword>
      <keyword majortopicyn="N">
       coronavirus infection
      </keyword>
      <keyword majortopicyn="N">
       pandemics
      </keyword>
      <keyword majortopicyn="N">
       pneumonia, viral
      </keyword>
      <keyword majortopicyn="N">
       virus diseases
      </keyword>
     </keywordlist>
     <coistatement>
      Conflicts of interest. None declared.
     </coistatement>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="received">
       <year>
        2020
       </year>
       <month>
        02
       </month>
       <day>
        19
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="accepted">
       <year>
        2020
       </year>
       <month>
        03
       </month>
       <day>
        20
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        8
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        8
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        8
       </day>
       <hour>
        6
       </hour>
       <minute>
        1
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      epublish
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32256547
      </articleid>
      <articleid idtype="doi">
       10.26633/RPSP.2020.40
      </articleid>
      <articleid idtype="pii">
       RPSP.2020.40
      </articleid>
      <articleid idtype="pmc">
       PMC7105280
      </articleid>
     </articleidlist>
     <referencelist>
      <reference>
       <citation>
        J Clin Virol. 2004 Dec;31(4):304-9
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         15494274
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Antiviral Res. 2014 Jul;107:84-94
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         24769245
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Autoimmun Rev. 2016 Jan;15(1):71-81
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         26384525
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Drug Discov Today. 2019 Mar;24(3):726-736
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         30711575
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Trials. 2018 Jan 30;19(1):81
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         29382391
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Int J Antimicrob Agents. 2020 Mar 20;:105949
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32205204
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        BMJ. 2019 Aug 13;366:l5140
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         31409588
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Lancet. 2020 Feb 15;395(10223):497-506
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         31986264
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        N Engl J Med. 2020 Mar 18;:
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32187464
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Clin Pharmacol Ther. 2010 Mar;87(3):322-9
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         20043009
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Anticancer Res. 2019 Nov;39(11):5891-5901
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         31704813
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Trends Microbiol. 2018 Oct;26(10):865-876
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         29759926
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Am J Chin Med. 2019;47(6):1223-1235
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         31505937
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        AIDS Res Hum Retroviruses. 2019 Jun;35(6):513-518
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         30909716
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Annu Rev Immunol. 2014;32:513-45
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         24555472
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Drug Discov Today. 2019 Jan;24(1):1-3
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         29936247
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Cell Res. 2020 Mar;30(3):269-271
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32020029
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Nat Rev Drug Discov. 2019 Jan;18(1):41-58
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         30310233
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Int J Antimicrob Agents. 2007 Oct;30(4):297-308
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         17629679
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Clin Infect Dis. 2018 May 2;66(10):1501-1503
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         29315362
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Nat Rev Drug Discov. 2020 Mar;19(3):149-150
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32127666
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Angiogenesis. 2004;7(4):335-45
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         15886877
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Drugs. 2018 Aug;78(12):1271-1276
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         30117020
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Nutrients. 2020 Jan 22;12(2):
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         31978969
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Eur Rev Med Pharmacol Sci. 2018 Aug;22(15):4956-4961
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         30070331
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        JAMA. 2020 Feb 7;:
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32031570
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        JAMA. 2020 Feb 5;:
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32022836
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Lancet. 2003 Oct 25;362(9393):1353-8
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         14585636
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Eur Rev Med Pharmacol Sci. 2020 Feb;24(4):2162-2164
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32141586
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Expert Rev Anti Infect Ther. 2017 Mar;15(3):269-275
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         27937060
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="Publisher">
     <pmid version="1">
      32253226
     </pmid>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       17
      </day>
     </daterevised>
     <article pubmodel="Print-Electronic">
      <journal>
       <issn issntype="Electronic">
        1946-6242
       </issn>
       <journalissue citedmedium="Internet">
        <pubdate>
         <year>
          2020
         </year>
         <month>
          Apr
         </month>
         <day>
          06
         </day>
        </pubdate>
       </journalissue>
       <title>
        Science translational medicine
       </title>
       <isoabbreviation>
        Sci Transl Med
       </isoabbreviation>
      </journal>
      <articletitle>
       An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice.
      </articletitle>
      <elocationid eidtype="pii" validyn="Y">
       eabb5883
      </elocationid>
      <elocationid eidtype="doi" validyn="Y">
       10.1126/scitranslmed.abb5883
      </elocationid>
      <abstract>
       <abstracttext>
        Coronaviruses (CoVs) traffic frequently between species resulting in novel disease outbreaks, most recently exemplified by the newly emerged SARS-CoV-2, the causative agent of COVID-19. Herein, we show that the ribonucleoside analog β-D-N
        <sup>
         4
        </sup>
        -hydroxycytidine (NHC, EIDD-1931) has broad spectrum antiviral activity against SARS-CoV-2, MERS-CoV, SARS-CoV, and related zoonotic group 2b or 2c Bat-CoVs, as well as increased potency against a coronavirus bearing resistance mutations to the nucleoside analog inhibitor remdesivir. In mice infected with SARS-CoV or MERS-CoV, both prophylactic and therapeutic administration of EIDD-2801, an orally bioavailable NHC-prodrug (β-D-N
        <sup>
         4
        </sup>
        -hydroxycytidine-5'-isopropyl ester), improved pulmonary function, and reduced virus titer and body weight loss. Decreased MERS-CoV yields in vitro and in vivo were associated with increased transition mutation frequency in viral but not host cell RNA, supporting a mechanism of lethal mutagenesis in CoV. The potency of NHC/EIDD-2801 against multiple coronaviruses and oral bioavailability highlight its potential utility as an effective antiviral against SARS-CoV-2 and other future zoonotic coronaviruses.
       </abstracttext>
       <copyrightinformation>
        Copyright © 2020, American Association for the Advancement of Science.
       </copyrightinformation>
      </abstract>
      <authorlist completeyn="Y">
       <author equalcontrib="Y" validyn="Y">
        <lastname>
         Sheahan
        </lastname>
        <forename>
         Timothy P
        </forename>
        <initials>
         TP
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA. sheahan@email.unc.edu rbaric@email.unc.edu.
         </affiliation>
        </affiliationinfo>
       </author>
       <author equalcontrib="Y" validyn="Y">
        <lastname>
         Sims
        </lastname>
        <forename>
         Amy C
        </forename>
        <initials>
         AC
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Zhou
        </lastname>
        <forename>
         Shuntai
        </forename>
        <initials>
         S
        </initials>
        <affiliationinfo>
         <affiliation>
          Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Graham
        </lastname>
        <forename>
         Rachel L
        </forename>
        <initials>
         RL
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Pruijssers
        </lastname>
        <forename>
         Andrea J
        </forename>
        <initials>
         AJ
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN, TN, 37232,USA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Agostini
        </lastname>
        <forename>
         Maria L
        </forename>
        <initials>
         ML
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN, TN, 37232,USA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Leist
        </lastname>
        <forename>
         Sarah R
        </forename>
        <initials>
         SR
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Schäfer
        </lastname>
        <forename>
         Alexandra
        </forename>
        <initials>
         A
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Dinnon
        </lastname>
        <forename>
         Kenneth H
        </forename>
        <initials>
         KH
        </initials>
        <suffix>
         3rd
        </suffix>
        <affiliationinfo>
         <affiliation>
          Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          Department of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Stevens
        </lastname>
        <forename>
         Laura J
        </forename>
        <initials>
         LJ
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN, TN, 37232,USA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Chappell
        </lastname>
        <forename>
         James D
        </forename>
        <initials>
         JD
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN, TN, 37232,USA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Lu
        </lastname>
        <forename>
         Xiaotao
        </forename>
        <initials>
         X
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN, TN, 37232,USA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Hughes
        </lastname>
        <forename>
         Tia M
        </forename>
        <initials>
         TM
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN, TN, 37232,USA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         George
        </lastname>
        <forename>
         Amelia S
        </forename>
        <initials>
         AS
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN, TN, 37232,USA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Hill
        </lastname>
        <forename>
         Collin S
        </forename>
        <initials>
         CS
        </initials>
        <affiliationinfo>
         <affiliation>
          Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Montgomery
        </lastname>
        <forename>
         Stephanie A
        </forename>
        <initials>
         SA
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Pathology &amp; Laboratory Medicine, University of North Carolina, Chapel Hill, NC, 27599, USA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Brown
        </lastname>
        <forename>
         Ariane J
        </forename>
        <initials>
         AJ
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Bluemling
        </lastname>
        <forename>
         Gregory R
        </forename>
        <initials>
         GR
        </initials>
        <affiliationinfo>
         <affiliation>
          Emory Institute of Drug Development (EIDD), Emory University, Atlanta, GA, 30322, USA.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          Drug Innovation Ventures at Emory (DRIVE), Atlanta, GA, 30322, USA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Natchus
        </lastname>
        <forename>
         Michael G
        </forename>
        <initials>
         MG
        </initials>
        <affiliationinfo>
         <affiliation>
          Emory Institute of Drug Development (EIDD), Emory University, Atlanta, GA, 30322, USA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Saindane
        </lastname>
        <forename>
         Manohar
        </forename>
        <initials>
         M
        </initials>
        <affiliationinfo>
         <affiliation>
          Emory Institute of Drug Development (EIDD), Emory University, Atlanta, GA, 30322, USA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Kolykhalov
        </lastname>
        <forename>
         Alexander A
        </forename>
        <initials>
         AA
        </initials>
        <affiliationinfo>
         <affiliation>
          Emory Institute of Drug Development (EIDD), Emory University, Atlanta, GA, 30322, USA.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          Drug Innovation Ventures at Emory (DRIVE), Atlanta, GA, 30322, USA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Painter
        </lastname>
        <forename>
         George
        </forename>
        <initials>
         G
        </initials>
        <affiliationinfo>
         <affiliation>
          Emory Institute of Drug Development (EIDD), Emory University, Atlanta, GA, 30322, USA.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          Drug Innovation Ventures at Emory (DRIVE), Atlanta, GA, 30322, USA.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          Department of Pharmacology and Chemical Biology, Emory University, Atlanta, GA, 30322, USA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Harcourt
        </lastname>
        <forename>
         Jennifer
        </forename>
        <initials>
         J
        </initials>
        <affiliationinfo>
         <affiliation>
          Centers for Disease Control and Prevention, Division of Viral Diseases Atlanta GA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Tamin
        </lastname>
        <forename>
         Azaibi
        </forename>
        <initials>
         A
        </initials>
        <affiliationinfo>
         <affiliation>
          Centers for Disease Control and Prevention, Division of Viral Diseases Atlanta GA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Thornburg
        </lastname>
        <forename>
         Natalie J
        </forename>
        <initials>
         NJ
        </initials>
        <affiliationinfo>
         <affiliation>
          Centers for Disease Control and Prevention, Division of Viral Diseases Atlanta GA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Swanstrom
        </lastname>
        <forename>
         Ronald
        </forename>
        <initials>
         R
        </initials>
        <affiliationinfo>
         <affiliation>
          Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          Department of Biochemistry and Biophysics, University of North Carolina at Chapel Hill, Chapel Hill, NC.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Denison
        </lastname>
        <forename>
         Mark R
        </forename>
        <initials>
         MR
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN, TN, 37232,USA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Baric
        </lastname>
        <forename>
         Ralph S
        </forename>
        <initials>
         RS
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA. sheahan@email.unc.edu rbaric@email.unc.edu.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          Department of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC.
         </affiliation>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <grantlist completeyn="Y">
       <grant>
        <grantid>
         R01 AI108197
        </grantid>
        <acronym>
         AI
        </acronym>
        <agency>
         NIAID NIH HHS
        </agency>
        <country>
         United States
        </country>
       </grant>
       <grant>
        <grantid>
         R01 AI132178
        </grantid>
        <acronym>
         AI
        </acronym>
        <agency>
         NIAID NIH HHS
        </agency>
        <country>
         United States
        </country>
       </grant>
       <grant>
        <grantid>
         U19 AI109680
        </grantid>
        <acronym>
         AI
        </acronym>
        <agency>
         NIAID NIH HHS
        </agency>
        <country>
         United States
        </country>
       </grant>
       <grant>
        <grantid>
         U19 AI142759
        </grantid>
        <acronym>
         AI
        </acronym>
        <agency>
         NIAID NIH HHS
        </agency>
        <country>
         United States
        </country>
       </grant>
      </grantlist>
      <publicationtypelist>
       <publicationtype ui="D016428">
        Journal Article
       </publicationtype>
      </publicationtypelist>
      <articledate datetype="Electronic">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        06
       </day>
      </articledate>
     </article>
     <medlinejournalinfo>
      <country>
       United States
      </country>
      <medlineta>
       Sci Transl Med
      </medlineta>
      <nlmuniqueid>
       101505086
      </nlmuniqueid>
      <issnlinking>
       1946-6234
      </issnlinking>
     </medlinejournalinfo>
     <citationsubset>
      IM
     </citationsubset>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="received">
       <year>
        2020
       </year>
       <month>
        03
       </month>
       <day>
        05
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="accepted">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        02
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        8
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        8
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        8
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      aheadofprint
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32253226
      </articleid>
      <articleid idtype="pii">
       scitranslmed.abb5883
      </articleid>
      <articleid idtype="doi">
       10.1126/scitranslmed.abb5883
      </articleid>
     </articleidlist>
    </pubmeddata>
   </pubmedarticle>
  </pubmedarticleset>
 </body>
</html>